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CHAPTER 1: REVIEW OF LITERATURE   
1.1 Introduction   
1.1.1 Stem Cells  
Stem cells have amazing potentials to develop into many different cell types during growth, 
especially early in life. Most importantly, many of these stem cells serve as internal repair systems, 
dividing without limit to replenish other cells and tissues (1). When stem cells divide, they can 
become another type of cell with a more specialized function, such as a brain cell or they can 
remain a stem cell. Stem cells have three notable characteristics: they are unspecialized, can self-
renew, and under physiological or experimental conditions, they can be induced to become organ-
specific cells (1). Scientists used to only have two kinds of stem cells to work with: embryonic 
stem cells (ESC) and non-embryonic adult stem cells. 
In mammalian development (Figure 1-1), only the zygote and early blastomeres are 
totipotent and can generate the whole organism (2). ESCs are derived from the inner cell mass 





Figure 1-1: Diagram of Genetic and Epigenetic Regulation of Pluripotency during Mouse 
Development. The totipotent zygote contains maternally inherited epigenetic modifiers and 
transcription factors, including Oct4, Sox2, and Exh2. These together with the embryonic 
transcripts regulate development to the blastocyst stage, where the pluripotent cells are established 
in the inner cell mass (ICM). Deletion of Oct4 and Nanog comprises the development of the ICM 
(8-10). In the post-implantation embryo, pluripotent epiblast cells are controlled by diverse 
repressive mechanisms during their differentiation into somatic and germ cell lineages (the latter 
of which undergo specification following repression of the somatic program). The early germ cells 
exhibit epigenetic and transcriptional states that are associated with pluripotency, and the ensuing 
epigenetic reprogramming within this lineage re-generates totipotency. The figure depicts the main 
epigenetic changes occurring during critical stages of development (2).  
 
The term pluripotent means that cells can differentiate into any cell of three germ layers: 
ectoderm, endoderm, and mesoderm (2-8). Pluripotent cells may differentiate to become 
multipotent progenitor cells, such as neural stem cells (NSCs), which then may differentiate into 
cell types of the neurogenic lineage only (1). Moreover, unipotent cells, such as skin cells, can 
only differentiate into only one cell type (3).  A summary of the different types of potency can be 




Table 1-1: Definitions of the Different types of Potency (3).  
Potency Sum of developmental options accessible to cell 
Totipotent Ability to form all lineages of organism; in mammals only the 
zygote and the first cleavage blastomeres are totipotent. 
Pluripotent Ability to form all lineages of body. Example: embryonic stem 
cells 
Multipotent Ability of adult stem cells to form multiple cell types of one 
lineage. Example: hematopoietic stem cells 
Unipotent Cells form one cell type. Example: spermatogonia stem cells (can 
only generate sperm) 
Reprogramming Increase in potency, dedifferentiation. Can be induced by nuclear 
transfer, cell fusion, genetic manipulation 
Transdifferentiation, 
plasticity 
Notion that somatic stem cells have broadened potency and can 
generate cells of other lineages, a concept that is controversial in 
mammals. 
 
In 1981, scientists discovered a way to derive ESCs from early mouse embryos, which led 
to the 1998 discovery of a technique to derive stem cells from human embryos to grow in the lab 
and are referred to as human embryonic stem cells (hESCs) (Figure 1-2) (9, 10). The first cultured 





Figure 1-2: How Embryonic Stem Cells are Derived. Adopted from the National Institute of 
Health (NIH) Web site www.stemcells.nih.gov (7).  
 
1.1.2 Neurodegenerative Diseases and Stem Cell Potential  
ESCs have been used as tools for studying developmental biology (11). More recently, 
ESCs have become of great interest in generating transgenic animals, drug screening, and potential 
cell therapies for regenerative medicine to address degenerative diseases (11). It has been realized 
that pluripotent cells possess the distinct potential to be utilized in the treatment of 






Figure 1-3: Characteristics of Embryonic Stem Cells. Adopted from the National Institute of 
Health (NIH) Web site www.stemcells.nih.gov (7). 
 
Neurodegeneration is a complex process that causes neuronal death in the central nervous 
system (CNS) and the peripheral nervous system (PNS), resulting in damage or dysfunction (12). 
“This damage further causes oxidative stress, axonal transport deficits, protein oligomerization, 
aggregation, calcium deregulation, mitochondrial dysfunction, abnormal neuron–glial 
interactions, neuroinflammation, DNA damage, and aberrant RNA processing” (12). There are 




Parkinson’s disease, Huntington’s disease, schizophrenia, amyotrophic lateral sclerosis, 
Alzheimer’s disease, and spinal muscular atrophy (5, 13). Many of the less broadcasted 
neurodegenerative disorders, though not less devastating, have been technically ignored (13).  
Fascinatingly, increasing age is the most consistent risk factor for developing a 
neurodegenerative disorder (11). Today, the growth rate of the population aged 65 and over has 
very much surpassed than that of the whole population combined (14, 15). Thus, many anticipate 
that, over the next generations, the proportion of elderly citizens will double. As expected, the 
proportion of persons suffering from neurodegenerative disorders will also be doubled, triggering 
an increased emotional, physical, and especially financial burden on society (15). 
The ability to isolate human embryonic stem cells (hESCs) is key for research and clinical 
applications. However, there are ethical concerns that come behind the use of human embryos for 
studies and cell therapies (5). One must also consider the complications of potential immune 
responses that some patients undergo during allogenic therapies (5). For these reasons, the ability 
to generate patient-specific somatic cell-derived induced pluripotent stem cells is of great interest 
to medical and scientific communities (5). In 2006, researchers made a discovery by classifying 
conditions that would allow some specialized adult cells to be genetically reprogrammed to assume 
an embryonic stem cell-like state called induced pluripotent stem cells (iPSCs) (5). From then on, 
scientists have developed techniques towards discovering more effective methods to reprogram 
somatic cells to other highly valuable stem cells.   
1.1.3 Network and Molecular Mechanisms of Pluripotency  
Mechanisms of pluripotency are still not entirely understood. However, scientists have 
clarified the master regulators of the pluripotency network; Sox2, Oct4, and Nanog (SON) proteins 




pluripotency (5 & 17). It has also been discovered that the expression of Oct4 is limited to the 
inner cell mass (ICM) in a developing embryo and is maintained in adult germ cells but 
downregulated in differentiated somatic cells (16 & 17). When scientists knockout Oct4 in 
embryos, they die after the blastocyst stage and fail to develop an ICM indicating its essential role 
in normal mammalian embryonic development (18). Moreover, reduced expression levels of Oct4 
in embryos leads to the spontaneous differentiation into the trophoblast lineages (18). This 
indicates the identity of Oct4 as part of a pluripotent maintenance mechanism (18). Furthermore, 
an increase in the expression levels of Oct4 in embryos, induces differentiation into primitive 
endoderm and mesoderm stages (19-21). Therefore, the Oct4 gene expression level precisely 
regulates the pluripotent state of ESCs.  
Sox2, (SRY-related HMG-box) is also a transcription factor that is highly expressed in the 
pluripotent lineage of the early embryos (22). Like Oct4, Sox2 plays an important role in 
maintaining pluripotency and its expression is confined to the ICM, epiblast of early embryos, and 
germ cells (22). In contrast to Oct4, however, Sox2 is also expressed in the extraembryonic 
ectoderm and in precursor cells in the early and adult nervous system (22 & 23). Moreover, Sox2 
knockout embryos fail to develop epiblast and die at the implantation stage (24). Additionally, a 
reduced level of Sox2 in ESCs is associated with a loss of pluripotency and a tendency to 
differentiate (25 & 26). Furthermore, it’s been reported that Sox2 and Oct4 work synergistically 
to control the expression of specific ESC genes by forming protein-heterodimers (26-28) and 
regulate expression of Oct4 itself (25). Moreover, Sox2 is a key component of the transcriptional 
regulatory networks, which maintains the totipotency of the cells during embryonic 
preimplantation period, the pluripotency of embryonic stem cells, and the multipotency of neural 




Nanog (homeobox protein) is also a transcription factor that was discovered based on its 
ability to maintain ESC self-renewal in the absence of leukemia inhibitor factor (LIF). LIF is used 
to maintain cultured mouse ESCs in an undifferentiated state (12 & 31). For instance, Nanog-null 
mouse embryos fail to maintain a pluripotent epiblast, while disruption of Nanog in vitro results 
in an increased tendency of ESCs to spontaneously differentiate (31 & 32). Nanog has been shown 
to act as a strong activator of Oct4 (33). “When the ESCs experience a drop in Nanog levels, they 
cause upregulation of transcription factors that are involved with trophectoderm differentiation, 
indicating that Nanog helps sustain pluripotency by repressing these differentiation factors” (32). 
Other reports suggest that Nanog is upregulated in embryonic based tumors (10). However, Nanog 
is not strongly correlated with cancers in human adults (20, 34). Sox2, Oct4, and Nanog, serving 
as master regulators, make up the pluripotency autoregulatory circuit, which maintains the 
pluripotency of ESCs (30) (Figure 1-4).  
The roles that SON transcription factors play during early development suggest that these 
master regulators are critical to a transcriptional regulatory mechanism that controls ESC identity 
(6). To find genes that are occupied by SON, scientists have utilized genome-wide location 
analysis and chromatin immunoprecipitation (ChIP) in hESCs (6). They found significant insights 
on the ability of these transcription factors to regulate the pluripotency of cells (10, 36). Firstly, 
SON proteins bind to their own promoters and to each other’s promoters to form an autoregulatory 
circuit (Figure 1-4) (6). Secondly, as regulators, SON mostly occupy their target genes to maintain 
pluripotency and repress differentiation. The autoregulatory circuit of the SON regulator system 





Figure 1-4: Schematic Diagram of Autoregulatory Circuit. SON form an interconnected 
autoregulatory circuit, by targeting both their own promoters and those of each other. In this way, 
the three key transcription factors can maintain their own expression, thereby contributing to the 
maintenance of pluripotency. Proteins are depicted as circles, gene promoters as rectangles. (6)  
  
SON factors have also been identified to target hundreds of other genes in ESCs (6) (Figure 
1-5), mainly including two types of ESC genes. The first type of gene family contains pluripotency 
genes, where the SON factors bind to the promoter regions of these genes to activate their gene 
expression. The second sets of genes include differentiation genes that remain silent until cell 
differentiation (10). During the embryonic state, the SON factors bind to the repressors of these 
second set of genes set to silence their gene expression. The activation of gene expression of this 
second set of genes causes differentiation and the SON factors bind to the promoter regions of 
these ‘silent genes’ to activate their gene expression for induction of differentiation. Therefore, the 
SON master regulator factors regulate a cell’s fate through the interactions with the promoters and 




autoregulatory circuit responses to external stimuli, which implies that pluripotency could be 
maintained through developmental stimuli (10). 
 
Figure 1-5:  Diagram of SON Transcriptional Network. The SON trio contribute to ESC 
pluripotency by repressing genes linked to lineage commitment and activating genes involved in 
pluripotency. Active genes include, besides Oct4, Sox2, and Nanog themselves, ESC-specific 
transcription factors, components of ESC signaling cascades, and epigenetic enzymes. In contrast, 
repressed genes comprise regulators of differentiation into the three germ layers and 
extraembryonic development.  Proteins are depicted as circles and gene promoters as rectangles 
(6).  
SON co-occupy different genes, meaning that they work together to maintain pluripotency 
(3-6). STAT3, SKIL, ZIC3, and REST are a few of the transcription factors that are transcribed 
for pluripotency. Chromatin-modifying enzymes such as SET or signal transduction components 
such as DKK of the Wnt pathway or Lefty2 of the TGF-β pathway are other genes for pluripotency 




‘silent’ differentiation genes that translate to proteins of the Polycomb group, chromatin 
remodeling complexes, and histone deacetylase complex (37). Moreover, expressed factors are all 
known to maintain the pluripotency of ESCs and their self-renewal, while the silent genes, such as 
Pax6, are involved with differentiation of the cells to specific lineages (10, 36). The expression of 
silent genes that translate to developmental transcription factors like Pax6, are associated with the 
differentiation to neurogenic lineage commitment. These factors have established the formation of 
models to uncover the downstream of cellular differentiation.  
1.1.4 Most Effective Stem Cells for Neurodegenerative Disorders 
Over the past 14 years, cell reprogramming techniques have been widely applied to 
generate induced pluripotent stem cells (iPSCs) (5, 38, 39). Many patient-specific iPSC-lines have 
been established for specific diseases such as Parkinson’s disease (40, 41, 46), Huntington’s 
disease (40) schizophrenia (42), amyotrophic lateral sclerosis (43), Alzheimer’s disease (44), and 
spinal muscular atrophy (45). However, for therapeutic application, iPSCs need to be efficiently 






Figure 1-6:  Generation and use of iPSC Modelling in Parkinson’s Disease (PD). Somatic cells 
from a diseased patient are isolated and then reprogrammed to a pluripotent state (iPSCs). iPSCs 
can be maintained in culture or induced to differentiate along tissue- and cell-type specific 
pathways. Differentiated cells can be used to elucidate disease mechanism pathways, as well as 
for the development of novel therapies (46). 
 
Moreover, the cells derived from iPSC and undifferentiated iPSCs exhibit potential 
tumorigenic risks (29, 47, 48, 49) and limit their direct use in cell transplantation applications. This 
makes PSC differentiation mechanisms highly attractive. With that said, Pluripotent stem cells 
such as ESCs and iPSCs can form teratomas in vivo, whereas multipotent, lineage-restricted stem 
cells such as induced neural stem cells (iNSCs) and hematopoietic stem cells do not (29, 47, 48, 
49). “Reprogramming somatic cells into less potent, lineage-restricted cells will sidestep the 
difficulty of differentiating iPSCs, thus lowering the risk of teratoma formation, while 
complementing iPSC technology” (29). 
Transcription factors have been previously used to induce a change in cell fate from one 
type of cell to another (5, 29, 38, 39, 50, 51, 54, 55). Induced multipotent adult stem cells such as 




have been generated from somatic cells. In particular, the generation of induced neuronal cells 
(iNCs) from somatic cells provided a new avenue for research in transplantation therapies for 
neurodegenerative disorders. Although iNCs have typical neuronal cell properties such as 
exhibiting proper electrical function in culture and can be generated with high efficiency (5%-
20%), clinical applications must consider the inability of iNCs to self-renew in culture because 
they are terminally differentiated (29). Terminally differentiated means that there is a restriction 
in cell fate to only a few neuronal sub-types. Moreover, current reprogramming methods generate 
a mixture of neuronal cells and other unknown types of cells, limiting the use of iNCs for 






Figure 1-7: Potential Stem Cells with Neural Capability. An illustration proposing the classes of 
mammalian stem cells that can give rise to neurons presented as a hierarchy beginning with the 
most primitive and multipotent stem cell and progressing to the most restricted. The restrictions of 
fate at each step and examples of sites in the body where they can be obtained are also presented. 
As our understanding of the true potential and nature of stem cells is still unfolding, modifications 
will be added. For example, the small arrows pointing up suggest the potential, although not well 
documented, dedifferentiation of the more restricted cell below (52). 
 
Although many studies have shown the generation of iNCs from mouse and human somatic 
fibroblast cells (53, 54, 55, 56, 57), these cells are terminally differentiated which results in a 
restriction in cell fate to only a few neuronal subtypes. In all, the generation of patient-derived 
multipotent iNSCs is more advantageous than the generation unipotent (iNCs) because multipotent 





1.1.5 Neural Stem Cells and Neurogenesis 
NSCs were first identified within the CNS in the year 1992 (58). Overall, the ability to 
efficiently reprogram somatic cells into self-renewable, multipotent, nontumorigenic, and neural-
linage restricted iNSCs, may have major implications in regenerative medicine for 
neurodegenerative diseases. “The most common brain cells are neurons and glial cells” (59). Glial 
cells are the astrocytes and oligodendrocytes of the CNS. NSCs are very powerful model systems 
for neurodegenerative disease transplantation therapies because they are only able to make three 
types of cells; astrocytes, oligodendrocytes, and neurons (Figure 1-8).  “Furthermore, NSCs 
secrete therapeutic molecules like soluble factors, including neurotrophic factors, growth factors, 
and cytokines, that protect existing neural cells against damage in situ” (60). Neurotrophic factors 
regularly released from NSCs improve a lesion’s microenvironment, therefore generating suitable 




Figure 1-8:  NSC Properties for Therapeutics. NSCs secrete soluble factors, including 
neurotrophic factors, growth factors, and cytokines, thus protecting existing neural cells against 
damage in situ. Furthermore, they differentiate into neurons, astrocytes, and oligodendrocytes via 
committed progenitor stages to replace lost neural cells. Either neural protection or cell 
replacement may aid in neurological functional recovery after acute or chronic injury via neural 
regeneration (60). 
 
Multipotent adult stem cells, which are adult stem cells such as hematopoietic stem cells, 
mesenchymal stem cells, and NSCs, exist throughout the adult human body and play important 
roles in tissue maintenance and repair. Until now, the reason for the age-associated decline in self-
renewing capability and differentiation potential of multipotent stem cells in tissues is unclear. 
Like pluripotent stem cells, multipotent stem cells can self-renew and proliferate. However, 
multipotent stem cells can only develop into multiple specialized cell types for specific tissue or 
organ versus pluripotent stem cells that can generate any cell in all three germ layers. The 




repairing the CNS. NSCs, with self-renewal ability that are multipotent and able to generate 
multiple neural lineages, including glia, and neurons, are derived from regions throughout the adult 
CNS (64). 
The major function of neurons is the transmit information mostly through biochemical 
mechanisms. The typical neuron consists of a cell body, dendrites specialized for receiving 
information from other neurons, and an axon specialized to conduct impulses away from the cell 
body. Astrocytes function as physical, and metabolic supporters for neurons, through 
detoxification, guidance during migration and regulation of energy metabolism. Moreover, 
astrocytes also serve as electrical insulation for unmyelinated axons. Astrocytes are also thought 
to play a vital role in regulating NSC proliferation and differentiation. Oligodendrocytes mainly 
function to provide support and insulation for axons in the CNS by creating the myelin sheath. 
Neurogenesis is the continuous natural growth and development of nervous tissue. Adult 
neurogenesis is an active process, where adult neural progenitors differentiate and mature into 
neuronal cells that integrate into the existing neural circuitry. In mammals, CNS neurogenesis 
occurs in two discrete locations called neurogenic regions: the subgranular zone (SGZ) of the 
dentate gyrus in the hippocampus for dentate granule cells and the subventricular zone (SVZ) of 





Figure 1-9:  Models on the Identities of Potential Quiescent NSCs in the Adult Brain. (A) Two 
neurogenic regions in the adult brain: the subgranular zone (SGZ) in the dentate gyrus (DG) of the 
hippocampus and the subventricular zone (SVZ) of the lateral ventricles (LV). (B) Potential 
lineage relationships in the adult SVZ. (C) Potential lineage relationships in the adult SGZ (64). 
 
The development of the mammalian cerebral cortex follows a stepwise production of 
neurons, then glial cells, including astrocytes and oligodendrocytes from NSCs (65). During 
embryonic development, cells of the central nervous system are derived from the neuroectoderm, 
which is arranged as a neural tube which later invaginates to form structures including the 
prosencephalon. Then the telencephalon is diencephalon emerge from the prosencephalon. The 
cerebral cortex arises from the dorsal telencephalon and the ventral telencephalon gives rise to the 





Injuries, such as stroke, activate the neurogenesis mechanism outside of the described 
neurogenic regions. However, whether and the extent of the active neurogenesis occurs outside the 
two neurogenic regions in the mammalian CNS in vivo remain debatable. Neurogenesis is reduced 
in the progression of aging, which is thought to contribute to age-related cognitive issues (66). The 
mechanism of age-dependent decline in neurogenesis remains largely obscure. 
1.2 Induced Neural Stem Cells (iNSCs) 
The generation of neurons or glial cells to replace damaged tissue is a key step in stem cell-
based therapies designed to treat neurodegenerative disease and neurological disorders (29). 
Although the mechanisms that establish and maintain the multipotency of neural stem cells are 
unclear, the generation of expandable NSCs is a promising therapeutic approach for treating 
neurodegenerative diseases or injuries. One approach is to obtain NSCs by differentiation of 
pluripotent embryonic stem cells (ESCs) as indicated on the right side of Figure 1-10. The second 
approach is to reprogram the skin fibroblast cells from the patients into expandable induced NSCs 
(iNSCs) as indicated in the left of Figure 1-10. The obtained expandable NSCs serve as the source 





Figure 1-10: Application of Pluripotent Stem Cells in Cell Therapy for Stroke-injured Brain. (1) 
Pluripotent stem cells can be derived from blastocyst (embryonic stem cells [ESCs]) or through 
reprogramming of postmitotic somatic cells, most commonly fibroblasts, generating induced 
pluripotent stem cells (iPSCs). (2) Both ESCs and iPSCs can be treated in vitro to generate glia 
and neurons. (3) Transplantation of glial and neuronal cells at the early stages of their development 
into stroke-injured brain can lead to functional recovery through the promotion of myelinogenesis 
and restoration of astrocyte network (glia) or by increasing cellular plasticity and restoring 
neuronal network (neurons). OPC an indicates oligodendrocyte progenitor cell (67). 
 
1.2.1 Generation of iNSCs using Defined Transcription Factors 
Certain Transcription factors (TFs) are lineage-determining factors, which activate 
necessary genes that determine a cell’s fate such as Sox2, Oct4, Klf4, and c-Myc factors. 
Yamanaka et. al., reprogrammed somatic fibroblast cells into ESC-like pluripotent stem cells, 




overexpressing certain neural-lineage TFs. Despite the differentiation capabilities of pluripotent 
stem cells, they were found to have ethical and practical issues (49). Specifically, the origin of 
ESCs and the ability of iPSC derived cells to form tetratomic cells, respectively (49). From this 
point on, many researchers have turned their focus towards reprogramming somatic cells to adult 
stem cells such as NSCs, which do not form tetratomic cells. 
Their et al. used the same reprogramming cocktail as Yamanaka (Oct4, Sox2, Klf4, and c-
Myc), but with the initial absence of Oct4 when reprogramming fibroblasts (68). In this case, cells 
are thought to abandon the initial pluripotent fate and enter the NSC multipotent fate by being 
overwhelmed by the overexpression of transcription factors (69). This result indicated that the TF-
driving cell reprogramming technique could be used to generate adult stem cell fates such as NSCs 
from somatic cells without going through the pluripotent state. Since then, scientists have spent 
major effort in searching different TFs to ensure a gain of insight on the minimal combinations of 
lineage-factors required to convert fibroblasts in iNSCs.  
NSCs show characteristic properties that differentiate them from other types of adult stem 
cells. For example, NSCs form self-renewable neuro-spheres, which can be serially passaged and 
assayed using different techniques such as immunostain for assaying NSC marker proteins and 
qRT-PCR for assaying NSC marker mRNAs. More importantly, NSC’s have the capability of 
differentiation into tri-neural lineage cells, including neurons, astrocytes, and oligodendrocytes, 
which is a key feature that can be used to characterize NSC’s.  
Recently, two studies have shown that the combination of Sox2, Klf4, and c-Myc or Brn4, 
Sox2, Klf4, c-Myc, and E47/Tcf3 can reprogram fibroblasts into iNSCs (70, 71). It is crucial here 
to omit Oct4 form the combination because the aim is to only induce NSC’s without pluripotency. 




factors that induce the NSC fate. The results from both reports showed impractical long conversion 
time of around 3 weeks, and very low conversion efficiencies of induced NSC’s from fibroblast 
cells (as low as 0.1%) (70, 71).  
Despite the low conversion efficiency, they demonstrated that when the potent c-Myc 
oncogene is overexpressed, the iNSCs can self-renew and generate functional neurons in vitro and 
integrate in vivo (70). In some cases, iNSCs established high self-renewal capacity with up to 130 
passages in culture (70). It seemed that c-Myc overexpression is the key factor for iNSC 
conversion. However, as seen in transplant studies, the overexpression of the c-Myc oncogene is 
correlated with increased brain tumorigenesis (72). Moreover, Lujan et al. were also able to 
generate iNSCs with the use of FoxG1 and Brn2 only (71). Further studies suggest that the 
successful induction of NSCs is due to the activation of the Sox2 gene expressions by FoxG1 (70, 
72). 
1.2.2 Sox2 and NeuroD1 are Two Key Factors for iNSC Fate Determination 
Up to now, it is still unclear which linage-determining factors are needed to efficiently 
reprogram fibroblasts into high-quality iNSCs. Regardless of what approach it takes to generate 
iNSCs from fibroblast cells, Sox2 seems to be a key factor. Sox2 is a master regulator factor that 
is highly used for NSC identity and maintenance (73). Sox2 expression can reprogram fibroblasts 
to multipotent NSCs (73). 
One report used only one transcription factor (Sox2) to generate iNSCs from human and 
mouse fibroblasts (29). In this study, iNSCs were shown to generate functional neurons in vitro 
and can survive in vivo without the formation of tumors or tetratomic cells (29). Results of this 
study also shows mouse-iNSCs (miNSCs) were passaged over 40 times, and around 20 passages 




potent populations, instead of a heterogeneous population containing different neural progenitor 
cells (29). 
In a cell, contrary to c-Myc overexpression, Sox2 overexpression was observed to become 
silent over time. This implies that iNSCs can switch, on or off, the endogenous expression of NSC 
fate-determining genes to maintain cell fate (29). Furthermore, Ring et al., also confirmed the 
advantages of NSCs over PSCs by transplanting mouse brain cells induced by Sox2 and observing 
the lack of tumor formation. (29). 
As discussed above, many cell reprogramming techniques and/or combinations can be 
performed to induce NSCs from fibroblasts, however, they all suffer from several of the following 
major challenges. First, they show very low reprogramming efficiency, probably partly due to the 
combination of TFs and partly due to the current gene-delivery based reprogramming technology. 
Second, all studies above used invasive methods such as a virus to force the gene expression of 
lineage- determining factors. “The use of a virus may have a major safety risk and possibly cause 
undesired tumor formation, genotoxicity, and mutagenesis” (74). Third, the current existing cell 
reprogramming procedures are less efficient, complicated, and expensive for practical use.  
Neuronal Differentiation Factor 1 (NeuroD1), is a basic helix-loop-helix lineage-
determining transcriptional factor (75). NeuroD1 is required for regulating the transcription of 
genes that cause neurogenesis and early differentiation of adult-born neurons (75). The 
combination of TFs along with NeuroD1 can be used to reprogram mouse fibroblasts into iNSCs 
with self-renewing ability (55, 68, 70, 131, 76). Moreover, one factor (Sox2) is enough to generate 
self-renewable, multipotent, nontumorigenic, and lineage-restricted iNSCs (29). However, these 




addition of neuronal fate-specifying factors to the reprogramming cocktail can influence the ability 
to generate specific neuronal subtypes with much higher conversion efficiency (54, 77). 
In my thesis project, I applied a patented reprogramming technology called QQ-protein-
induced pluripotent stem cell (QQ-piPSC) technology, developed in Dr. Jianjun Wang’s 
laboratory. This piPSC technology allows for protein-induced cell reprogramming to generate 
piPSCs from somatic cells with over 90% conversion efficiency (137). I used this breakthrough 
technology to reprogram fibroblast cells into protein-induced NSCs (pi-NSCs) and eliminated the 
need for any invasive and unsafe methods in the traditional gene-based cell reprogramming 
techniques. Second, we believed that the addition of the NeuroD1 factor along with the Sox2 factor 
would lead to significantly enhanced efficiency of reprogramming fibroblasts into piNSCs with 
high quality and less safety risk. Third, we demonstrated high differentiation potential of the 
generated pi-NSCs into high quality and safe specialized neurons, astrocytes, and oligodendrocytes 
in vitro. 
1.2.3 NSC Differentiation   
Here, we focus on the early steps of ESC neurogenesis, in which multiple protocols have 
been established that produce pluripotent cell‐derived iNSCs. Recent studies suggest that ESC‐
derived NSCs can have the properties of embryonic radial glia, that can proliferate and generate 
all types of neural derivatives, neurons, astrocytes, and oligodendrocytes (78). During early 
development, the radial glia cells are the primary neural stem cells (NSCs) that generate all the 
neurons as well as the glial cells and ependymal cells that persist in the CNS (79). In the embryo, 
neurogenic radial glial cells are present throughout the developing CNS (79). 
Two approaches have been identified to make NSCs from ESCs. One fascinating method 




cell-cell interactions and signals through EB formation (80). It was found that when mouse ESCs 
were removed from a feeder layer and suspended without LIF growth factor that was a 
maintenance factor for pluripotency, they aggregate to form an outer layer of hypoblast‐like cells 
(extraembryonic visceral endoderm) surrounding an epiblast-like core collectively referred to as 
an EB (primitive ectoderm) (81 & 82). The epiblast-like core in EBs can generate cell derivatives 
of all three primary germ layers (endoderm, mesoderm, and ectoderm) (83). At this point, the EB 
core continues to express the ESC marker Oct4 and starts to express the primitive ectoderm marker 
FGF5 (81, 82, 84). The ectoderm is known to develop into the nervous system, among other types 
of tissues such as hair, nails, eyes, and ears. Furthermore, the EB core may also be committed to 
the ectoderm which is characterized by the expression of Sox2 (81 & 82). At this point, a 
morphological transformation occurs to the columnar epithelium and it starts to look like a neural 
tube, which is then followed by the expression of neurectoderm‐specific markers such as Sox1 
(81 & 82). Moreover, conditions that direct the differentiation of the EB core towards 
neuroectoderm will further increase the pool of cells that can differentiate into neurons and glial 
cells (81 & 82). 
It has been identified that signals released from the embryos anterior extraembryonic 
visceral endoderm (AVE) promote the differentiation of the anterior neuroectoderm and the 
visceral endoderm, EB derived ESCs behave similarly (85). However, the notochord signals 
known for structuring the neural tube, are not present in the EB derived from ESCs (86). For this 
reason, EBs derived from ESCs are able to generate primitive ectoderm, but not neuroectoderm or 
neurons (81). This is because the signaling molecule Indian Hedgehog, which is required for the 




differentiation (80). Several other studies have shown an additional role of the hedgehog signaling 
cascade in NSC proliferation in the embryo and adult mouse brain (87, 88, 89, 90).  
Other studies show that the addition of retinoic acid (RA) can significantly increase the 
generation of neural lineage cells. RA has a well-established dorsoventral patterning role during 
development in CNS tissue (91 & 92), and ESC derivatives (93). Cells treated with RA, yield of 
up to 40% neuron‐like cells, versus just a few percent observed in the cultures without RA (80). 
Similar methods that utilize RA treatment, increased the yield of neural derivatives, including 
glutamatergic neurons and motor neurons (92, 94, 95). However, when neural progenitors 
generated by RA induction showed a limited capacity to differentiate when transplanted into the 
neural tube of chick embryos, compared with ESC‐derived neural progenitors generated in the 
absence of RA (96). Further drawback includes the presence of a heterogeneous mixture of cells 
as the final product.  
Others have also tried to include other factors, such as the use of MEDII medium which 
appears to have signals that are capable of inducing neuroectoderm differentiation (80).  These 
NSCs do not appear to have a restricted regional identity and, when subjected to different signaling 
factors, can be further induced to generate neurons or glia, as well as neural crest cells (82). 
However, the molecules in the medium responsible for this activity, Hep‐G2–conditioned 
medium, have not been classified and this method has not yet been applied to hESCs. 
The EB selection in defined media mimics the embryo environment and this method 
combines the use of an EB intermediate, in which cells of all three primary germ layers arise, 
followed by a neural lineage-specific selection step (97-99). During the first several days of culture 
non‐neuro-ectoderm cells, including undifferentiated ESCs, extraembryonic endoderm and 




on the expression of Nestin, Sox1, Sox2, and other NSC markers (97). NSCs generated using this 
approach have been used to give rise to a variety of specific neural and glial derivatives, including 
oligodendrocytes (100), dopaminergic neurons, and glutamatergic neurons (101, 95). The strength 
of this method is the relative purity of the final product and the ability to generate large numbers 
of NSCs upon FGF2 addition (80).  The weaknesses of mimicking the embryo environment in 
defined media include the extended time it takes to generate NSCs (10-14 days) and, the constant 
variability in the final quality of the product. The final products are usually contaminated with 
mesodermal derivatives, likely due to the multiple steps (80) yeilding heterogeneous populations.  
Neurogenesis of ESCs provides an in vitro culture system that can be used to characterize 
the progenitor cell types involved in the differentiation, identify the active growth factors, and 
signaling molecules of Neurogenesis (78). Studies show that Wnts and BMPs retrain ESC neural 
differentiation, specifically by inhibiting the differentiation of primitive ectoderm and primitive 
NSCs (78). Leukemia inhibiting factor (LIF) supports this inhibition, probably by supporting the 
maintenance of ESC and primitive ectoderm survival (78). In contrast, Notch and FGF4 promote 
the commitment of cells to the neural lineage and FGF promotes the proliferation of committed 
cells like primitive NSCs (78). RA seems to have a role in ESC neural induction, however, findings 
that identify its mechanism are not clear (80). Other data shows that VEGFA promotes the survival 
of mature NSCs and inhibits the survival of the primitive NSCs (78). Which implies that these 
growth factors and signals function in all stages of development to regulate differentiation, 





Figure 1-11: Growth Factors and Signaling Molecules Regulate the Multistep Transition from 
Embryonic Stem Cell (ESC) to Neural Stem Cell (NSC). (A) Oct4‐positive ESCs first 
differentiate into primitive ectoderm‐like cells (prim ecto), which express fibroblast growth 
factor‐5 (FGF5) as well as Oct4. These cells then differentiate into primitive NSCs (prim NSC), 
characterized by the expression of moderate levels of nestin and Sox1, and a rounded morphology. 
These cells differentiate into NSCs with an elongated‐radial glia‐like morphology that express 
high levels of nestin and Sox1. LIF, Wnt, bone morphogenetic protein (BMP), Notch, FGFs, 
Hedgehog (Hh), and vascular endothelial growth factor‐A (VEGFA) influence this process as 
shown. (B) Images of ESC, prim ecto, prim NSC, and NSCs generated using the direct defined 
medium monolayer culture approach (protocol 6) showing expression of FGF5 in prim ecto, 
Sox1‐GFP (green fluorescent protein) in prim NSCs and NSCs. Note the elongated morphology 
of NSCs. Another method to generate NSCs from ESCs is to the deprive ESCs of both cell–cell 
interactions and signals by low density culture in serum‐free medium, triggering a mechanism for 
NSC differentiation (78). 
 
It is clear that we have just begun to understand the complex cell inducing interactions that 
regulate ESC neurogenesis. The addition of specific factors, at specific stages, will allow scientists 
to optimize the production of NSCs, neurons and, glial cells for transplantation therapies designed 




1.3 Cell Reprogramming Methods  
Many studies have been performed to improve the reprogramming methods and to apply 
technology to understanding potential treatments. As mentioned before, iNSCs complement iPSC 
technology which includes the molecular techniques used to reprogram to the two types of stem 
cells. Many have established methods to induce the conversion of fully differentiated cells into 
iPSCs or iNSCs (Figure 1-12) (3).  
Figure 1-12: Four Strategies to Induce Reprogramming of Somatic Cells. (i) Nuclear transfer 
involves the injection of a somatic nucleus into an enucleated oocyte which, upon transfer into a 
surrogate mother, can give rise to a clone (“reproductive cloning”), or, upon explantation in 
culture, can give rise to genetically matched embryonic stem (ES) cells (“somatic cell nuclear 
transfer”, SCNT). (ii) Cell fusion of somatic cells with ES cells results in the generation of hybrids 
that show all features of pluripotent ES cells. (iii) Explantation of somatic cells in culture selects 
for immortal cell lines that may be pluripotent or multipotent. At present, spermatogonial stem 
cells are the only source of pluripotent cells that can be derived from postnatal animals. (iv) 






Up to now, four methods have been developed to reprogram somatic cells. Nuclear 
transplantation (NT), the fusion of somatic cells and ESCs, culture-induced reprogramming, and 
viral transduction. NT is the introduction of a nucleus from a donor somatic cell into an enucleated 
oocyte to generate a cloned animal (102).  The ability to generate cloned animals implicated that 
the epigenetic status of differentiated cells is not permanent, and cells can be reprogrammed to an 
embryonic cell that can develop into an organism (3). However, this process is inefficient (3). It 
was also found that less differentiated cells are more capable of epigenetic reprogramming, greatly 
reducing the efficiency when reprograming abundant somatic cells such as fibroblasts (3). Further, 
the cloning of stem cells was found to be much more efficient than differentiated cells (103, 104, 
105). Although NT-induced cells show no molecular or biological differences with ESCs fertilized 
from fertilized embryos (105 & 106). These data implicate that NT ESCs are very useful, but the 
NT method can only be used with rare unfertilized human oocytes which provides a need for more 
practical methods when considering ethics (107).   
The second method is the fusion of ESCs with somatic cells. This method has been shown 
to reprogram somatic murine nuclei to an undifferentiated state (107-109).  The resulting cells 
contain many parental embryonic features, such as the activation of Oct4 markers or activation of 
the somatic X chromosome, suggesting that the pluripotent phenotype is dominant (3). However, 
the inefficiency of these fussed ESCs with somatic cells has shown to be inefficient and the 
resulting cell is a tetraploid that limits their potential in clinical applications because of the risk of 
generating large-scale genetic instability (3).    
A third method to reprogram cells is called the culture-inducing reprogramming, which is 
cell explantation in culture. This involves the removal of living tissue, placed in a medium for 




(3). Presently, spermatogonia stem cells are the only source of pluripotency from postnatal animals 
(3). Other embryonically sourced ESCs from blastomeres or the ECM and embryonic germ cells 
(EGCs) can be expanded in culture and be functional in germlines (3). However, we are interested 
in reprogramming somatic cells to generate adult stem cells that are present in postnatal animals. 
Moreover, it is unknown whether somatic stem cell-derived cells, like those from spermatogonia 
stem cells, are truly pluripotent since scientists have failed to show significant findings (3). 
The fourth cell reprogramming method, viral infection of reprogramming TFs, so-called 
Yamanaka iPSC technique, which suffers from several major challenges: 1) Very low 
reprogramming efficiency (< 0.1%); 2) Using integrating virus to deliver pinpointed transcription 
factor (TF) genes, causing major safety concerns; 3) Very complicated procedure which is 
expensive for future human clinical applications (134). Moreover, viral vectors may be randomly 
integrated into the host genome which increases the risk for undesired genotoxicity, mutagenesis, 
and tumor formation.  
1.3.1 Reprogramming by Defined Transcription Factors-Gene Delivery  
In 2006, Takahashi and Yamanaka generated mouse ESC-like cells from mouse somatic 
cells through viral-mediated transduction of the transcription factors Oct4, Sox2, Klf4, and cMyc 
with selection for the activation of the Oct4 target gene Fbx15. These generated cells were termed 
as induced pluripotent stem cells (iPSCs). They displayed morphology like that of ESCs (Figure 
1-13A). Reverse transcription PCR (RT-PCR) analysis of iPSCs revealed the expression of ESC 
markers Oct3/4, Nanog, Dax1, Zfp296, E-Ras, Cripto, and Fgf4 (Figure 1-13B). iPSCs were also 
confirmed to be pluripotent by their ability to form teratomas (Figure 1-13D). Although unable to 
generate live chimeric mice, iPSC clones were injected into blastocysts and were found to 





Figure 1-13: Characterization of iPSCs Derived from Adult Mouse Tail Tip Fibroblasts. (A) 
Morphology of iPS-TTFgfp4-3 on STO feeder cells. (B) RT-PCR analysis of ES marker gene 
expression in iPS-TTFgfp4 cells (clones 1-5 and 7). They used primer sets that amplified 
endogenous but not transgenic transcripts. (C) Contribution of iPS-TTFgfp4-7 and iPS-TTFgfp4-
3 cells to mouse embryonic development.  iPS cells were microinjected into C57/Bl6 blastocysts.  
Embryos were analyzed with a fluorescence microscope at E7.5 (upper panels, iPS-TTFgfp4-7P) 
or E13.5 (lower panels, iPS-TTFgfp4-3). Scale bars = 200 µm (upper panels) and 2 mm (lower 
panels). (D) The E13.5 chimeric embryo was sectioned and stained with anti-GFP antibody 







On the other hand, to maintain the pluripotent state of iPSCs, they require the continuous 
viral expression of SON genes.  Furthermore, it was found that the endogenous Oct4 and Nanog 
genes were highly methylated and expressed at lower levels or not at all when compared to ESCs.  
This implicated that these iPSCs and ESCs are similar, but not identical.  
The cell reprogramming method used suffers from several major challenges. Firstly, they 
have found very low reprogramming efficiency (< 0.1%). Secondly, viral transduction procedures 
are complicated, expensive, and have a major safety concern for future human clinical 
applications. Pluripotency depends on tightly regulated levels of pluripotency genes and it has 
been shown that a minimal increase or decrease of Oct4 levels causes differentiation (20).  More 
studies have shown that iPSCs could be successfully generated without viral integration into 
specific sites (110), such as plasmid transfection (72) or non-integrating adenovirus (111), 
nevertheless, these methods all suffer very low reprogramming efficiency. Thus, retroviral 
integration methods are not likely to be the reason for the inefficiency.    
In 2007, researchers demonstrated that selection for expression of the endogenous Nanog 
and Oct4 genes, instead of the Fbx15, resulted in full reprogrammed pluripotent cells unlike 
Yamanaka’s Fbx15-iPSCs just a year before (112 & 113). This implicates that even a slight 
increase or decrease of Oct4 could change the cell fate. In this case, like ESCs, iPSC expression 
of the endogenous Nanog and Oct4 genes were found to have hypomethylated Nanog and Oct4 
promoters (112 - 114).  
Human iPSCs were generated by retroviral introduction, using different sets of 
transcription factors into fibroblasts (50-51). Takahashi et al. and Park et al. both showed iPSC 
being generated by using Yamanaka’s reprogramming cocktail (Oct4, Sox2, Klf4, and cMyc). 




generated human iPSCs that were able to differentiate into cell types of all three germ layers in the 
dish and formed mature teratomas upon injection into mice (39). The iPSC from Yu et al. more 
closely resemble ESCs through morphology, patterns of DNA methylation and histone 
modifications, gene expression profiles, and expression of telomerase.  Other groups have also 
reported the successful generation of human iPSCs from somatic cells, offering a great tool for 
regenerative medicine (40, 43, 115-119).   
1.3.2 Reprogramming by Defined Transcription Factors-Protein Delivery   
Yamanaka’s and related methods cause many concerns. One major concern is the safety of 
these iPSCs when they are used for human clinical applications. Many modified genetic methods 
have been developed and have generated iPSCs with less risk (120).  However, they still utilized 
genetic materials and always risked unexpected genetic modifications by the exogenous sequences 
in target cells (120). A few years later, in 2009, it was found that directly delivering the four 
recombinant reprogramming proteins (Oct4, Sox2, Klf4, and cMyc) to reprogram somatic cells 
into ESC-like iPSCs. The resulting pluripotent cells are referred to as protein-induced pluripotent 
stem cells (piPSCs) (120, 121).  Instead of the previous method that depends on the transcription 
of delivered genes, this method avoids introducing exogenous genetic modifications to the target 
cells by delivering the transcription factors themselves into the target cells. 
The difficulty of accomplishing this direct delivery of proteins is passing the plasma 
membrane into the cell. This challenge was solved using cell-penetrating peptide (CPP), a short 
peptide sequence that contains a high amount of basic amino acids (e.g. arginine or lysine) which 
are attached to the c-terminus of the reprogramming proteins (121).  Researchers employed poly-
arginine CPPs and determined that the CPP-tagged recombinant proteins readily entered the cell 




One group initiated their protein delivery method by first establishing stable HEK293 cell 
lines that expressed each Oct4, Sox2, Klf4, and cMyc fused with a nine arginine (R) CPP and a 
Myc tag to surpass the plasma membrane (122). The HEK293 extracts were then incubated with 
human dermal neonatal fibroblasts (HDFn) and the intracellular translocation of proteins was 
observed by immunocytochemistry by using antibodies (Figure 1-14A) (121). They found that the 
efficient intracellular translocation of each reprogramming protein and translocated to the nucleus. 
By testing HEK293 cell extracts they found that repeated protein treatment cycles (16 hours 
protein treatment followed by 6-day incubation in ES media) yielded human p-iPSCs (Figure 1-
14B) especially after three to four cycles yielded to iPSC-like morphology (Figure 1-14C, top 
panel). However, induced cells failed to show alkaline phosphatase (AP) activity, suggesting that 
the reprogramming was incomplete. However, and approximately half of these colonies were 
found to be AP positive starting from the sixth cycle (Figure 1-14D).    
AP-positive colonies of iPSCs were characterized as similar to hESCs and maintained for 
more than 35 passages and shared common morphological characteristics and expressed markers 
such as Oct4 and Nanog similar to hESCs (Figure 1-14C). Furthermore, the qRT-PCR analysis 
also found similar characteristics such as the high expressions of endogenous mRNAs of ESC 
markers such as Sox2, Oct4, and Nanog similar ESCs (Figure 1-15A). The protein human-induced 
p-hiPSCs also formed EBs which were able to differentiate into cells of all three germ layers 
(Figure 1-15D).  Further testing found global gene-expression analysis to be similar to hESCs and 
different from HDFn (Figure 1-15B). Moreover, after transplantation of p-hiPSCs inside the 
kidney capsule of mice formed teratomas within 6-8 weeks (Figure 1-15E).  p-hiPSC lines also 
showed similar Bisulfite sequencing analyses to hESCs. For instance, p-hiPSCs and hESCs 




HDFn (Figure 1-15C). These data confirmed that p-hiPSC are pluripotent both in vitro and in 
vivo. 
 
Figure 1-14: Generation of Protein-Induced hiPSC Lines by Direct Delivery of Reprogramming 
Proteins Fused with 9R as a CPP. (A) HNFs were incubated with HEK293 extracts expressing 




were counterstained with DAPI. (B) The schematic protocol depicts a repeated process and the 
timeline for generating phiPSCs from HNFs. (C) (Top panel) shown are starting HNFs (first 
image), morphology after three-cycle protein treatments (second image), and increased colony 
number after six cycles (third image). Approximately half of these iPS-like colonies stained 
positive for AP; early morphology after p-hiPSC colonies were transferred to MEF is shown 
(fourth image), and morphology of established p-hiPSC line is shown at passage number 10 (p-
hiPS01 [fifth image] and p-hiPS02 [sixth image]). Immunostaining of p-hiPS01 (middle panel) 
and p-hiPS02 (bottom panel) clones show expression of hESC markers, including AP, SSEA-2, 
SSEA-4, Oct-4, Nanog, and Tra1-60. Nuclei were stained with DAPI (blue in the second and third 
row of the panel). (D) Shown is the efficiency of reprogrammed colony formation with iPS-like 
morphology and AP-positive staining after different numbers of the protein treatment cycle.  This 
is the summary of three independent experiments with the standard error (121). 
 
 
Figure 1-15: Characterization of p-hiPSC Lines. (A) Quantitative RT-PCR was performed to 
assess the expression of c-Myc, Gdf-3, Klf4, Nanog Oct4, Rex1, Sox2, and hTERT in p-hiPS01 
and p-hiPS02, hES (H9), and HNF cells. Relative gene expression represents fold changes relative 
to that of HNF cells normalized to β-actin expression. This experiment (repeated twice in triplicate 
using independently prepared cDNAs) resulted in almost identical patterns. (B) The global gene-
expression patterns were compared between p-hiPS01 and HNF, and between p-hiPS01and H9 
with Affymetrix microarrays. The red lines indicate the diagonal and 5-fold changes between the 
paired samples. (C) Bisulfite sequencing analysis of the Nanog and Oct4 promoters reveals almost 
complete epigenetic reprogramming. Open and closed circles indicate unmethylated and 
methylated CpG, respectively. Numbers on the top show each CpG location. Percentages of CpG 
methylation (%Me) are shown. (D) In vitro differentiation of p-hiPSCs. Immunostaining images 
(first and second-row panels) show all three germ layer cells at day 24, including neural 
(ectodermal), muscle and endothelial-like (mesodermal), and endoderm-like cells (endoderm). (E) 




teratomas. The resulting teratomas contained tissues representing all three germ layers (p-hiPS01, 
first row; and p-hiPS02, second row): ectoderm, epidermal and neural tissue (rosette); mesoderm, 
bone and cartilage; and endoderm, respiratory epithelium and intestinal-like epithelium (121). 
  
 P-hiPSC technology offers a new and potentially safe method for generating patient-
specific stem cells (121).  By eliminating the manipulation of the genome and DNA transfection, 
p-hiPSCs are appropriate for potential clinical applications and research (121).  However, the p-
hiPSC colonies took double the amount of time it takes with viral transduction, about 8 weeks, and 
much lower efficiency (~0.001%) when compared to virus-based methods (~0.01%) suggesting 
that the published piPSC method are not efficient and require the implementation of new methods 
(38, 39, 123, 134).  
1.3.3 Reprogramming by Defined Transcription Factors-RNA Method  
In 2010, specific synthetic modified messenger RNA (mRNA) that code for 
reprogramming factors is delivered directly to cells (124). Through in vitro transcription (IVT), 
mRNA was made by PCR amplicons along with the removal of 5‟ triphosphates to activate PKR 
to repress protein translation, the addition of guanine cap for successful translation and increase 
the half-life, and modified ribonucleotides to further the minimization of innate immune responses 
to transfected RNA. They found that modified RNAs in addition to interferon inhibitor B18R 
brought upon high protein expression levels and high cell viability (124). By using a cationic 
vehicle to facilitate endocytosis of modified mRNAs that code for the necessary reprogramming 
factors, they were able to generate RNA-iPSCs (RiPSCs) from human fibroblasts (124). However, 
to sustain high levels of protein expression, the transfection of modified RNAs had to be done 
daily. RiPSC colonies are then mechanically picked and expanded in ESC permissive conditions 
to establish iPSC lines for characterization. Bisulfite sequencing showed demethylation patterns 




RiPSCs displayed the expression of pluripotency genes such as SON and revealed RiPSCs having 
a molecular signature like ESCs and distinct from fibroblasts.  
The pluripotency-associated transcript genes including Sox2, Oct4, Nanog, Rex1, Lin28, 
and DNMT3B of RiPSCs were upregulated in the RiPSCs compared to fibroblast lines. The 
embryonic bodies generated for RiPSCs were able to differentiate into cell types of all three germ 
layers. Lastly, the pluripotency of these cells was confirmed by their ability to form teratomas 
when injected into the kidney capsules of mice. This method of inducing PSCs yielded within 17 
days and higher reprogramming efficiency (~2%), versus the viral methods which usually take 4 
weeks for colonies to emerge. In all, this method also eliminates the risk of genomic integration 
and insertional mutagenesis. However, this method is very complex and is very difficult to be used 
for human clinical applications. 
1.4 Methods for Characterization of iNSCs  
To prove that iNSCs have been generated, it is necessary to fully characterize them and 
show the similarities to naturally occurring NSCs. It is also necessary to show their distinct 
differences from the cell type they originated from. Many methods can be used to determine 
whether iNSCs are multipotent, with some of these methods have been mentioned previously in 
this chapter; here is a summary of the common methods.  
1.4.1 Colony Formation of iNSCs 
The observance of ESC-like morphology is commonly used as the initial form of 
characterization for iPSCs. ESCs display round shaped colonies, large nucleoli, and scant 
cytoplasm (4) and display the ability to form closely packed colonies with a clear edge, distinct 
from the surrounding cells. Accordingly, NSCs form neurospheres, which are similar to ESC 




that are commonly used as the parental cells as a somatic cell source. During cell reprogramming, 
the observation of typical iNSC colony morphology, the efficiency of colony formation, and 
increased doubling time provide good preliminary indicators if the reprogramming protocol is 
working and if there is any iNSC formation.  However, the cells must meet more stringent criteria 
to be considered multipotent iNSCs.     
1.4.2 Immunostaining   
Immunocytochemistry of the immunostaining of NSC markers is another technique that is 
frequently used to characterize iNSCs.  This is accomplished by using antibodies to detect the 
presence of specific NSC marker proteins. The detection of common NSC marker proteins during 
cell reprogramming of the starting somatic cells into iNSCs may indicate a switch or transition in 
the transcriptional gene network of the somatic cells to the one that resembles NSCs. 
Immunostaining of the cells is commonly performed in comparison with both the starting 
fibroblast cells, as a negative control, and the reprogrammed cells during or after cell 
reprogramming as an indication of the formation of iNSCs.  
1.4.3 Western Blot   
Western Blot is also used to detect the presence of NSC marker proteins in the newly 
generated iNSCs.  In a western blot, cell extracts are prepared, and the proteins contained within 
are typically separated by size using SDS-PAGE gel electrophoresis before being transferred to a 
membrane. The membrane is then incubated with an antibody against a specific protein for a 
certain amount of time, and, washed with PBS to remove unbound antibody, then incubated with 
a secondary antibody, which will bind to the primary antibody.  This secondary antibody is linked 
to a reporter enzyme that, when incubated with substrate, will indicate the presence of the primary 




1.4.4 qRT-PCR  
Reverse transcription-polymerase chain reaction (qRT-PCR), is the most well-known 
technique for absolute and relative quantification of mRNA transcription level (125). The 
expression of target genes is often standardized to reference genes to eliminate sample-to-sample 
partialities. Reference genes are genes that are expressed constantly in all cells to maintain 
essential cellular functions (126). In this study, it is imperative to identify the appropriate reference 
genes before qRT-PCR, since the accuracy of qRT-PCR is highly reliant on reference genes. 
Furthermore, qRT-PCR is another technique used to detect the mRNA levels of up-
regulations of the common NSC marker gene expressions. In RT-PCR, mRNA extracted from cell 
samples is reverse transcribed to cDNA, which is then amplified through the use of primers and a 
DNA polymerase enzyme, as in traditional PCR. While immunostaining and western blotting 
detect the presence of specific proteins, this method detects the presence of mRNAs the code for 
specific proteins. While the qRT-PCR technique serves as an indication for the amount of 
transcription of a particular gene, it does not guarantee that these transcripts will be properly 
translated into a fully functional protein. Only a combination of the positive results in 
immunostaining/western blot and qRT-PCR of a particular NSC marker of the reprogrammed cells 
indicates the up-regulation of both gene transcription and protein translation of this NSC marker, 
thus reliably indicating the success of the cell reprogramming of fibroblast cells into iNSCs. 
1.4.5 DNA Demethylation Analysis   
DNA demethylation analysis is the process of removing a methyl group from the 
nucleotides of DNA. After an injury to nerves in mammals, DNA demethylation plays an 
important role in neuro-regeneration (160). DNA methylation occurs on cytosine at CpG sites on 




promoter is associated with transcriptional activation and gene expression (156). In all, these are 
called epigenetic changes.  
DNA demethylation analysis of promoters of the NSC marker genes of the reprogrammed 
cells is also commonly carried out via bisulfite genomic sequencing analysis to determine the 
epigenetic state of these cells.  In this process, bisulfite is used to determine the methylation pattern 
of the DNA. Once the fibroblast cells are reprogrammed into iNSCs, the demethylation level of 
the NSC marker gene is significantly decreased as compared with that of the starting cells, 
indicating transcriptional activation and gene expression of this NSC marker gene.  
1.4.6 In Vitro Differentiation   
In vitro differentiation is utilized as a method for determining the developmental potential 
of the reprogrammed iNSCs. NSCs possess the potential to differentiate into neurons and glial 
cells, including astrocytes and oligodendrocytes. Therefore, the differentiation of the 
reprogrammed iNSCs into astrocytes, oligodendrocytes, and neurons indicates as to whether or 
not they are multipotent.  In this process, the reprogrammed NSCs are cultured in the medium that 
induces neural differentiation.  
1.4.7 In Vivo Differentiation   
When the GFP-labeled mouse iNSC (miNSC) neurospheres were microinjected into the 
cortex of pups. Immunostaining revealed that miNSCs survived and differentiated into NeuN-
positive neurons with mature-looking dendritic spines, Oligigo2-positive oligodendrocytes, and 
GFAP-positive astrocytes 5 days after transplantation (Figure 1-16). So, miNSCs were shown to 





Figure 1-16:  miNSC-Derived Functional Neurons In Vitro and Multipotency of miNSCs In Vivo. 
(A and B) Neurons derived from subclones miNSC-A21-B3 or miNSC-A21-B6 at 14 days in 
culture express MAP2 (green) and Synapsin (red), a presynaptic marker of mature neurons. (C) A 
patched neuron derived from miNSC-A21-B3 at 17 days in culture. (D and E) Whole-cell 
capacitance and membrane resistance of neurons derived from miNSC-A21 were determined from 
a transient 5 mV hyperpolarizing step from a holding potential of –70 mV. Values are mean ± 
SEM. (F) Current-clamp recordings of neurons derived from miNSC-A21 at –40 mV reveal action 
potentials with stepwise current injection. (G) Voltage-clamp recordings of neurons derived from 
miNSC-A21 reveal both fast inactivating inward and outward currents indicating functional 
voltage-dependent Na+ and K+ channels. (H–P) GFP-labeled miNSC-A21 were grown in 
suspension cultures for 1 day to generate small neurospheres and then microinjected into the cortex 
of P2–P3 wild-type pups. Five days after transplantation, mouse brains were collected, fixed, 
sectioned, and immunostained. (H–J) Immunostainings reveal that miNSC-A21 can differentiate 
into NeuN+ neurons (H and I) with mature-looking dendritic spines (J) in vivo. (K–M) miNSC-
A21 can also differentiate into GFAP+ astrocytes in vivo. (N–P) miNSC-A21 can also differentiate 
into Olig2+ oligodendrocytes in vivo. Scale bars represent 2 μm in (A) and (B) and 10 μm in (C) 
and (H)–(P) and include genetic analyses, epidemiology, statistics and studies in animal models. 
iPSC technology expands the opportunities for research. Patient-derived iPSCs can be used to 
examine the disease process at a cellular level. iPS cells can be used to test response to possible 
drugs and might be used to develop patient-specific therapy (29).  
 
Since the generation of iNSCs has been achieved by many investigators (70, 57, 29, 127), 
a study of in vivo long-term survival rates, multilineage differentiation, and the functional 




the cortex of adult female immunodeficient mice (8 weeks; ∼25 g; n = 9; Figure 1-17). iNSCs 
were labeled using retroviral transduction along with a GFP-coding vector to distinguish 
transplanted cells from the surrounding tissue. Cells were passaged at least two times and three 
washing steps to make sure no remaining virus particles are present in the iNSCs, which may 
induce endogenous cells after transplantation.  
Six months after transplantation, an overview analysis revealed a significant long-term 
survival rate in the cortex and hilus and, a densely packed graft core was detected at the injection 
site and a less densely organized fraction of migrating cells that integrated within the existing 
network. However, immunostain analysis has revealed that transplanted cells do not express the 
NSC marker, Nestin, the cell-cycle marker, KI67, or the neural progenitor marker, DCX (Figure 
1-17) (128). This implies that iNSCs have lost their stem cell identity after grafting and therefore 





Figure 1-17: iNSC-Derived Cells Show In Vivo Long-Term Survival Rates and a Multilineage 
Differentiation Potential. (A) Schematic overview (left) of the two transplantation target sites in 
the adult mouse brain: (1) the cortex and (2) the hilus of the dentate gyrus. Six months after 
transplantation, an immunohistological analysis (right) revealed a sound survival rate of the GFP-
labeled iNSCs in both regions. Image 1 displays a maximum intensity projection (MIP). Red 
dashed lines indicate the hippocampus. (B) iNSC-derived cells do not express the cell-cycle 
marker KI67 (upper panel) or the neural progenitor marker DCX (lower panel). The images 
represent the MIPs of a confocal z stack. (C and D) iNSCs at graft edges or those that had 
substantially migrated outside of the graft differentiate into TUJ1- (C) and NEUN-positive (D) 
neurons and showed an orientation and shape comparable with the neighboring endogenous 
neurons when transplanted into the cortex. (E and F) Transplanted iNSCs of the hilus migrate and 
integrate into the granule layer of the dentate gyrus and express the neuronal marker TUJ1 (E) and 
NEUN (F). Dashed lines indicate the regions of magnification. (G) iNSC-derived NEUN-positive 
cells transplanted into the hilus integrated into the existing network and extended the CA3 region 
of the hippocampus. Dashed lines indicate the region of magnification. (H) In both regions, iNSCs 
differentiated into the glial lineage indicated via the astrocyte marker GFAP (upper panel; MIP of 
a confocal z stack) and the oligodendrocyte marker OLIG2 (lower panel; the left image represents 





The authors also analyzed the differentiation potential of iNSCs 6 months after 
transplantation by immunofluorescence staining using neuron-specific class III-beta-tubulin 
(Tuj1), for immature neurons, and NeuN, which is only expressed in mature neurons (Figures 1-
17) (128). Moreover, these induced cells integrated into the neuronal network and astonishingly 
displayed identical orientations and shapes to the surrounding endogenous neurons (128). iNSCs 
that experienced neuronal differentiation migrated and integrated into the granule cell layer of the 
dentate gyrus (Figure 1-17). This process has been found to be like differentiation of the 
endogenous neural stem cells of the SGZ (subgranular zone) (129). 
1.5 Future Clinical Applications of iNSCs  
The ability to reprogram somatic cells into self-renewable iNSCs has major implications 
for future clinical application to treat neurodegenerative diseases. iNSCs can also serve as a model 
system for revealing disease pathogenesis, drug screening, toxicity tests, cell transplantation 





Figure 1-18:  Overview of Different Approaches to Disease Modeling. Generation and 
Applications of patient-specific disease models. Primary cells of patients can be used for disease 
modeling, but they are not easily available and cannot be expanded in culture. Adult stem cells or 
induced pluripotent stem cells (iPSCs) can be expanded in culture and differentiated into the 
disease-affected cells that can be used to recapitulate disease pathogenesis in vitro. Patient-specific 
disease models can be used to identify new biomarkers for improved diagnostic procedures, such 
as earlier detection of disease onset. For example, hyperphosphorylated mitogen-activated protein 
kinases (MAPKs) and microtubule-associated protein tau (MAPT) have recently been associated 
with early susceptibility to neurodegeneration using patient-specific models of Parkinson's disease 
with mutant leucine-rich repeat kinase 2 (LRRK2)29. These disease models can also be used to 
identify compounds that alleviate disease pathology in vitro, which can be further developed into 
novel drugs. Such compounds can be identified by targeting a novel pathway that is dysregulated 
in the disease model or, alternatively, by carrying out a phenotypic screen using the disease model 
to identify compounds that may act through novel mechanisms. Stem-cell-derived cells can also 




1.5.1 Cell Replacement for Regenerative Medicine  
NSCs, which exist in various regions of the CNS throughout the mammalian lifespan, can 
be expanded and induced to differentiate into neurons and glia in vitro and in vivo. Because of 
these characteristics, there have been increasing interests in the identification and characterization 
of NSCs and neural progenitor cells both for basic developmental biology studies and for 
therapeutic applications to the nervous systems. Transplantation of NSCs or their derivatives into 
a host brain and the proliferation and differentiation of endogenous stem cells by pharmacological 
manipulations are potential treatments for many neurodegenerative diseases and brain injuries, 
such as Parkinson's disease, brain ischemia, and spinal cord injury. Continued progress in NSC 
research is providing a new future for brain repair.  
1.5.2 NSC Drug Discovery and Toxicology Research   
Neurological diseases such as Alzheimer’s disease and Parkinson’s disease are emerging 
major problems for human health, as average life expectancy is increasing globally. Drug 
discovery for neurological disease remains a major challenge. Poor understanding of disease 
pathophysiology and incomplete representation of human disease in animal models hinder 
therapeutic drug development. Advances with iNSCs can enable modeling of human diseases on 
a personal basis with the patient derived NSCs and neural cells. Utilizing iNSC-derived neurons 
also advances drug compound screening and evaluation of drug efficacy. These cells have the 
genetic backgrounds of patients that more precisely model disease-specific pathophysiology and 
phenotypes. Therefore, applications of human iNSCs or iNSC-derived neurons are a new direction 
for drug discovery in neurodegenerative diseases. 
Drug testing identifies potential therapeutic compounds and increases understanding of 




ADME NSC models is thought, throughout the medical community, to have a strong impact on 
drug discovery and development. Human NSCs could be used for testing different drugs and toxic 
environmental agents in developmental neurotoxicity studies (131). Mature neurons provide useful 
drug safety screens for neurotoxicity and synaptic dysfunction (131). In the presence of reliably 
expandable and physiologically relevant models, drug discovery processes become less costly. 
Benefits also include more relevant research for the clinic.  
Patient-specific neural cells could change the world of drug development for 
neurodegenerative disease treatment. An estimated 40% of drug candidates are abandoned 
throughout the development pipeline due to unforeseen adverse reactions in humans (132) and 
adverse drug reactions are still the fourth leading cause of death in the United States, indicating 
that current testing practices do not sufficiently predict clinical toxicity (131).  Since the human 
nervous system displays unique complexity and patterns of gene expression, the potential use of 
these patient-derived neural cells could increase the predictability of clinical trials from preclinical 
studies because current animal models used for toxicity are not always predictive of human 
response. Also, these patient-derived NSCs and neurons precisely record the patients’ genetic 
background which is critical for drug developments in neurodegenerative disease treatment since 
patients’ genetic background may show the pathology of the patients at the molecular level.  In 
2002, the research community found that human neurons react differently to toxin, as compared 
with mouse brains in a vaccine clinical trial for Alzheimer’s disease plaques. The vaccine is AN-
1792, showed severe cases of meningoencephalitis in humans that were not shown to occur in 
rodent safety studies (133).  
In all, in vitro toxicology assays from human iNSCs and their derivatives can offer 




human transformed cell lines, largely due to improved relevance and greater versatility. More 
relevant human NSC-based assays should translate into safer drugs, lower attrition rates, and a 
































CHAPTER 2: MOLECULAR CLONING AND RECOMBINANT PROTIEN 
PRODUCTION 
2.1 Goal  
The application of induced Neural Stem Cells (iNSCs) in science and medicine, in place 
of iPSCs or ESCs, not only eliminates the controversy of utilizing human embryos to derive stem 
cells (4) but also the potential to increase the efficiency of obtaining the desired cell. In contrast 
with allogenic approaches that use a single source of cells to treat many patients, patient-specific 
somatic cell-derived iNSCs avoids the risk of immunologic rejection in regenerative medicine 
studies (39). Protein-based iPSC (piPSC) technology has provided safer opportunities for 
biomedical research and clinical application (134). Complimenting piPSC technology with even 
safer piNSCs with fewer differentiation options further increases the magnetism of this technology. 
Furthermore, our protein-induced reprogramming technique eliminates DNA transfection and 
genome manipulation, which results in human piNSCs that are appropriate for drug discovery, 
disease modeling, and potential human clinical applications for neurodegeneration (121).  
The viral method of reprogramming described in the previous chapter has been used to 
reprogram somatic cells into iNSCs but faces many challenges.  Firstly, this method is time-
consuming, taking 35 to 65 days to achieve cell reprogramming of human somatic cells into iNSCs 
(120, 121). The Extended timeline renders the current iNSC technology useless for the treatment 
of the disorders that demand rapid treatment. Secondly, the increased culture time makes the 
current iNSC technology expensive for patients (120, 121). The current induced reprogramming 
technology also faces major challenges, such as a very low conversion efficiency of 0.01% of 
somatic cells into human piPSCs (120, 121) or hpiNSCs. Low conversion efficiencies are primarily 




suffers several setbacks (135, 136).  The CPP fusion method has low protein delivery efficiency 
because the delivered proteins are sensitive to intracellular proteases, causing degradation before 
the delivered proteins reach their target intracellular compartment to carry out their functions 
(135). CPP fusion method also lacks the capability to deliver the proteins into the nuclei for cell 
reprogramming (135). The resulting low efficiency of protein-induced reprogramming impedes 
the study of the mechanism of reprogramming and prevents its application in the clinical setting.   
The goal of this study was to develop a simple, fast, and efficient piNSC technology using 
four reprogramming proteins. We reduce current reprogramming protocols to one simple 
incubation step of somatic fibroblast cells directly with our four bacterially expressed transcription 
factors to achieve the generation of piNSC within one week. We also sought to achieve nearly 
~90% cell conversion efficiency by utilizing our QQ-protein delivery technology, a high yield 
bacterial expression protocol, and an in vivo protein refolding system.    
The QQ-protein delivery technology is developed in our lab that solves the problems 
associated with the CPP-protein delivery method (137, 138). This technology involves an 
incubation step of our proteins with the QQ-reagent which is polyethyleneimine (PEI) based (137). 
The QQ-reagent noncovalently associates to the protein surface to maintain the proteins original 
configuration. The QQ-reagent modified protein has targeting capability to deliver the protein to 
the specific intracellular compartments based on the localization signal sequences carried by the 
delivered proteins. QQ-modification of the protein also protects the delivered proteins form 
degradation by intracellular proteases (137).  
Our lab has a very high-efficiency bacterial expression method, which allows us to prepare 
high yields of pure proteins (139). Our method uses a tightly controlled induction by IPTG and 




recombinant proteins. This method obtained a much higher yield of recombinant proteins than the 
bacterial expression system or the human cell expression system employed by the other groups 
(120, 121). Our high-efficiency bacterial expression method can reduce the cost of reprogramming.    
The bacterially expressed protein may not be folded properly. The in vitro protein refolding 
protocols have been developed by many groups to properly refold the functional proteins (120).  
However, these in vitro protein refolding techniques require an additional purification step that is 
inefficient, making the reprogramming proteins expensive. Our QQ-protein delivery technology 
gives us the capability of in-cell protein refolding, which is a technique that enables the direct 
delivery of bacterially expressed proteins to the correct intracellular compartment of mammalian 
cells for intracellular folding machinery to efficiently refold the proteins (134, 137 & 138).  In the 
case of cell reprogramming, we can directly deliver the QQ-modified recombinant reprogramming 
proteins into the human dermal neonatal fibroblast (HDFn) cells, refold the proteins, and then 
transport them to the cell nuclei to initiate cell reprogramming to generate piNSCs (134, 137 & 
138).  
As described above, Sox2 was found to reprogram fibroblasts to iNSCs (29). However, 
further neural linage differentiation factors such as NeuroD1 are necessary to effectively 
differentiate iNSCs to astrocytes, oligodendrocytes, and neurons. In our reprogramming protocol, 
QQ-modified SON pluripotent reprogramming factors are used as a tool to quickly drive the 
human somatic fibroblasts to a transient pluripotent state, followed by Sox2 to generate iNSCs. 
The generated iNSCs shall rely on endogenous gene expression of the NSC factors to express NSC 
markers and resemble wild-type NSCs in their morphology, self-renewal, and gene expression 
profiles. Next, NeuroD1 is used to guide neural-lineage specific differentiation and the generated 




oligodendrocytes, as confirmed by the cell morphology and their specific biomarker protein 
expressions.  
In all, we apply our cell reprogramming technology to generate protein-induced neural 
stem cells (pi-NSCs) from fibroblasts using defined TFs. Using Sox2, we will generate pi-NSCs 
from human fibroblasts that are self-renewable, multipotent, nontumorigenic, and lineage-
restricted cells. Secondly, we will optimize our cell-reprogramming procedure specific for NSC 
generation to achieve greater than 90% conversion efficiency. Lastly, we will use NeuroD1 to 
differentiate the generated pi-NSCs into neurons, astrocytes, and oligodendrocytes in vitro and in 
vivo. 
2.2 Molecular Cloning - Materials and Methods  
The molecular cloning of Sox2, Oct4, Nanog, and NeuroD1 genes into an in-house high-
level bacterial expression vector of pET30a-sHT was previously done in Dr. Jianjun Wang’s lab 
by a previous graduate student in a paper to induce iPSCs. I was not involved in this molecular 
cloning work. Here I just go through the process of molecular cloning of all four proteins. The 
selected reprogramming genes were amplified by PCR and subcloned into a high-level protein 
expression vector pET30a-sHT. The correct sequence vectors were then transformed into bacterial 
cells for bacterial expression. The expression of the bacterial proteins was carried out following 
the traditional IPTG induction method. This is then followed by a purification process that uses a 
His-tag column followed by QQ-modification. 
2.2.1 Genes for Subclone, and Bacterial Expression Vector  
Four genes were chosen for subclone-Oct4, Sox2, Nanog, and NeuroD.  Each of the four 
genes (Oct4, Sox2, Nanog, and NeuroD) were obtained from Addgene.  Oct4, Sox2, Nanog were 




NeruroD1 was chosen because it’s a neural-linage differentiation factor with an ability to 
sufficiently induce neuronal differentiation of neural progenitors (140). 
Oct4 (NM_002701), is a member of the octamer-binding (Oct) family of transcription 
factors. Oct4, as described in the previous chapter is a key regulator of stem cell pluripotency (17). 
Although Oct4 is also a known oncogene and its abnormal expression is implicated in dysplastic 
growth and the formation of several types of cancer (141), it is essential for mammalian 
development (17).  
Sox2 (NM_003106), is an SRY-related HMG-box (Sox) transcription factor. Sox2 is 
highly expressed in the pluripotent cells of the early embryo and plays an important role in 
maintaining potency of stem cells (11, 142). Sox2 is also a master regulator gene for NSC identity 
and maintenance, as shown by the fact that knocking down Sox2 expression leads to immediate 
cell cycle exit and terminal differentiation of NSCs (143, 73). In ESCs, Sox2 has been found to 
form heterodimers with Oct4 to synergistically control the expression of ESC-specific genes (27, 
28, 134). Multipotent cell lineages in early mouse development also depend on Sox2 function 
(142). Mutations of Sox2 genes are involved with cancers and many other pathological human 
disorders (134, 144-146).      
Nanog (NM_024865) is a homeobox transcription factor and is a key master regulator of 
pluripotency. In ESCs, low levels of Nanog cause the upregulation of transcription factors 
associated with differentiation, implicating that Nanog may help sustain the pluripotent state by 
repressing these factors (33 & 147). Sox2, Oct4, and Nanog (SON) bind to their own promoters 
and to each other’s as an autoregulatory circuit (6).  
NeuroD1 (NM_028456), is a basic helix loop helix transcription factor expressed in the 




heterodimerizes with the products of the E2A gene and controls the transcription of a variety of 
genes by identifying and binding E boxes in their promoter region. NeuroD1 could convert 
Xenopus ectoderm into fully differentiated neurons and that it could prematurely differentiate 
neural precursor cells in the nervous system (148). NeuroD1 is sufficient to induce neuronal 
differentiation of neural progenitors in regions that normally do not show the addition of new 
neurons (140). 
For bacterial expression of the reprogramming genes, our lab used an engineered pET30a 
expression vector by Novagen (Figure 2-1). The pET30a was mutated via PCR using specifically 
designed PCR primers; the long His-tag was replaced by a short His-tag (six histidine residues) 
and a Factor Xa cleavage site could be inserted, adding the capability of removal of short his-tag 
from the reprogramming proteins (134, 149).  Replacement of the long his-tag with a short his-tag 
reduces the risk of the tag interfering with the proper folding of proteins (134, 149). When 
interference in proper folding and function of the protein occurs, we turn to our option to remove 
the His-tag by utilizing factor Xa cleavage sites and this vector was named pET30a_sHT (Figure 
2-2) (134).    
Along with a short His-Tag coding sequence, pET30a_sHT vector contains, a T7 lac 
promoter, and for gene insertion, a multiple cloning site (MCS) that contains cleavage sites for 
different and unique restriction enzymes (NcoI, EcoRV, BamHI, EcoRI, SacI, SalI, HindIII, NotI, 
and XhoI) (134). Downstream of the T7 promoter, there is a lac operator, which allows us to induce 
the expression of proteins using Isopropyl β-D-1-thiogalactopyranoside (IPTG) reagent (134). The 
function of IPTG is to molecularly mimic allolactose. In our case, a lactose metabolite triggers the 






Figure 2-1: pET30a Expression Vector (Novagen).  (A) Diagram of pET30a expression vector.  









  pET30a_sHT  
                                                                 Nco I            EcoRV bamHI EcoRI   
  atgcaccatcatcatcatcattcttctAAGGCCATGGCTGATATCGGATCCGAATTC  
  
           Sac I      Sal I     HindIII        Not I        Xho I  
  GAGCTCCGTCGACAAGCTTGCGGCCGCACTCGACACCACCACCACCACCACTGA 
  
Figure 2-2: Sequence map of engineered pET30a_sHT (134). 
  
2.2.2  Primer Design and PCR  
For primer design, they began with two single-stranded RNA primers, a forward 5‟ primer, 
and a reverse 3‟ primer. For amplification, the reverse 3‟ primer contained a sequence of bases 
that are the reverse complement of the 3‟ end of the DNA coding sequence and the forward 5‟ 
primer was designed to contain a base sequence identical to the 5‟ end of the DNA coding 
sequence. When conducting PCR on genes for subcloning, restriction enzyme (RE) cleavage sites 
that are present in the vector, must be coded into the forward and reverse primers for digestion 
later in the process to achieve the ligation reaction (134).    
Forward and reverse PCR primers are designed for each of the four genes. The forward 
primers contain bases that are identical to the 5‟ end of the coding DNA strand, and the reverse 
primers were designed to contain a sequence of bases with reverse complementarity to the 3‟ end 
of the coding DNA sequence, and are encoded with restriction enzyme cleavage sites that will be 
used for digestion by the specific restriction enzyme later in the process.. They were designed in 
this fashion to safeguard the proper annealing to the 3‟ end of the non-coding DNA, and coding 
strand respectively. To safeguard proper binding of restriction enzyme, six extra bases ware 




Mastercycler Personal PCR Machine using the following the PCR recipe (Table 2-1) and PCR 
process (Figure 2-3). 
Table 2-1: The PCR Recipe for PCR Reaction. 
PCR grade water (39 µl) 
reverse primer (1.5 µl)  
forward primer (1.5 µl) 
template DNA (1.0 µl) 
dNTP (1.0 µl) 
DNA polymerase enzyme (1.0 µl) 
10 x Buffer (5.0 µl) 
 
PCR Program  
  
Initialization step  96°C for 3 min 
Cycle  
Denaturation    94°C for 1.5 min 
  Annealing  60°C for 1.0 min 
  Elongation    68°C for 2.0 min 
Figure 2-3: PCR Program. This program was followed for PCR amplification of each of the four 
genes-Oct4, Sox2, Nanog, and NeuroD1. The Eppendorf Mastercycler Personal PCR Machine was 
programmed to these specifications and the cycle was repeated 30 times for each amplification 
reaction (134).  
 
2.2.3  Restriction Enzyme Digestion and Purification of PCR Products  
To remove any DNA fragments from the PCR products, they are purified through a 
Clonetechchroma spin +TE-400 column. At this point, the products are digested by the specific 
restriction enzymes encoded in their primers, and samples of pET30a_sHt vector were also 
digested with an identical restriction enzyme for ligation (134, 150). The DNA was then incubated 
for approximately 3 hours in a 37ºC water bath with restriction enzyme, a corresponding buffer, 
BSA, and water.  
After digestion, each of the digestion products was run on an agarose ethidium bromide 




a Qiagen-QIAEXII Gel Extraction Kit and run on a 10% agarose ethidium bromide gel by 
electrophoresis for confirmation. 
2.2.4 Ligation of Genes into Expression Vector and Transformation of the Ligated DNA into 
Competent Bacterial Cells 
In a ligation reaction, an enzyme referred to as DNA ligase links two sticky ends of each 
gene covalently (150). The ligation reactions occur overnight in an incubator at 4ºC of the purified 
digested PCR gene product, the purified digested vector, 10 x ligase buffer, PCR grade water, and 
DNA ligase enzyme.  Electrophoresis is then run to confirm the presence of ligation products.   
The ligated DNA is then transformed into E. coli cells. Our lab used the heath shock method 
for transformation (150). Here, the ligated DNA is transferred ER2566 E. coli competent cells 
through temperature changes for DNA to undergo transformation into E. coli cells. The cells are 
incubated (37°C) in plates rich LB medium with kanamycin so that only those bacterial cells that 
successfully taken up our vector with the resistance gene can survive. The next day, colonies are 
selected and placed in rich LB medium with kanamycin until the optical density 600nm (OD600) is 
~1. The culture is then combined with 1/4th the amount of glycerol to make glycerol stocks and 
placed in -80°C for protein expression later in our study. 
2.2.5 Screening for Positive Colonies and DNA Sequencing 
Here members of my lab utilized the QIAprep Spin Miniprep Kit for the isolation of 
plasmids from bacteria cells to determine if plasmid DNA contains each of the genes of interest. 
The silica-gel-membrane technology can bind DNA, from which the DNA can be eluted with. The 
resulting DNA solutions are then run on a 1% agarose ethidium bromide gel by electrophoresis 




gene size. The digestions follow the same digestions listed for PCR. The plasmids are then sent 
away for DNA sequencing for DNA sequence conformation.  
2.3 Molecular Cloning – Results (This was previously done by Wang’s lab)    
2.3.1 Primer Sequences and PCR Products 
The designed forward and reverse PCR primers for each reprogramming gene based on the 
gene sequences (Figure 2-5).  All forward and reverse primers contain six initial 5‟ bases to serve 
as spacer nucleotides to allow for binding of the restriction enzyme (150).  Following the six spacer 
nucleotides, a restriction enzyme cleavage site was encoded for each. The rest of the 24 bases of 
the forward primer are designed to be identical to the first 24 bases of the gene sequence. The 
reverse primer followed a similar design but used the reverse complement of the 3‟ end of the 
coding gene sequence, for proper annealing to the coding DNA strand. 
The restriction enzyme maps for the Oct4 gene indicates that there were no cleavage sites 
for NcoI, BamHI, EcoRI, SacI, or SalI present in the gene sequence. We then selected the highly 
efficient NcoI for the forward primer and EcoRI for the reverse primer (Table 2-2). The restriction 
enzyme map of the Sox2 gene indicated that there were no cleavage sites within the gene sequence 
for BamHI, EcoRI, SacI, and SalI, HindIII, NotI, and XhoI. For the forward primer, we selected 
was the BamHI cleavage site and HindIII for the reverse primer (Table 2-2). The restriction 
enzyme map of Nanog indicates that there were no cleavage sites within the gene sequence for 
EcoRI, SacI, SalI, NotI, and XhoI.  For the forward primer, we selected EcoRI, and XhoI for the 
reverse primer (Table 2-2). The restriction enzyme map of the NeuroD1 gene indicated that there 
were no cleavage sites within the gene sequence for EcoRI, SacI, SalI, NotI, and XhoI. For the 





Table 2-2: Forward and Reverse PCR Primers for each of the Four Reprogramming Proteins. 
Gene  PCR Primer 
(Forward/Reverse) 
Forward PCR Primer 
Sequence  






5’ cca att gga tcc atc gaa 
ggt cgt atg tac aac atg 
atg gag acg gag 3’ 
5’ cgg ttt aag ctt tca cat 






5’ cca att gcc atg gct atc 
gaa ggt cgt atg gcg gga 
cac ctg gct tcg gat 3’   
5’ cgg ttt gaa ttc tca gtt 
tga atg cat ggg aga gcc 
3’ 
 
Nanog NcoI/XhoI 5’ cca att gaa ttc atc gaa 
ggt cgt atg atg gtg gat 
cca gct tgt ccc 3’ 
5’ cgg ttt ctc gag tca cac 
gtc ttc agg ttg cat gtt cat 
gga 3’                           
NeuroD1 NcoI/XhoI 5’cca att gaa ttc atc gaa 
ggt cgt atg atg gtg gat 3’ 
5’ cgg ttt ctc gag tca cac 
gtc ttc agg ttg cat 3’ 
 
2.3.2  Digestion of PCR Products and Ligation 
In order to successfully ligate the reprogramming genes into the pET30a_sHT expression 
vector, each gene and a sample of the vector had to be digested with restriction enzymes (150).  
Proper restriction enzyme digest results in the formation of sticky ends on each gene and vector, 
giving the ability for sequences to line up for proper ligation. Each gene, and a sample of 
pET30a_sHT, are digested with the corresponding restriction enzymes that were coded for in the 




We then use agarose gel electrophoresis of the digested product for purification of these 
digested products including both digested PCR product and digested vector. After purification, the 
purified DNA will be used to run an agarose gel to visualize the purified DNA fragments for the 
PCR product and vector to decide the amount of each DNA fragment used in the ligation reaction.  
2.3.3 Plasmid Prep of Transformed Ligation Products and Positive Colony Screening  
 After identifying the ligation products on an agarose gel, they are transformed into 
BL21[DE3] competent E. coli cells.  The transformed cells were grown up on LB plates containing 
kanamycin to select for E. coli colonies that have taken up the pET30a_sHT expression vector 
with the kanamycin resistance gene. Plasmid prep was then performed on colonies that showed 
growth to verify the uptake of the expression vector. This was done for each of the four 
reprogramming genes, Sox2, Oct4, Nanog, NeuroD1.   
2.3.4 DNA Sequencing  
For each of the four genes, two of the plasmids that contained a gene of appropriate size 
based on the gel electrophoresis results were sent for DNA sequencing to confirm the inserted gene 
identity. Positive plasmids were identified for each of the four genes, and the bacteria containing 
these positive plasmids were then used for protein expression. Glycerol stocks of each of the 
positive bacterial cultures were properly labeled and stored in -80°C for use in protein expression. 
2.3.5  Conclusions-Summary of Results  
Forward and reverse PCR primers were designed for each of the four reprogramming 
genes-Sox2, Oct4, Nanog, and NeuroD, based on the gene sequences, the efficiency of available 
restriction enzymes on either of the four genes or the multiple clone sites of the pET30a-sHT. PCR 




by restriction enzymes encoded in their forward and reverse primers of the PCR products and with 
the vectors of pET30a_sHT.  
The Sox2 PCR product was digested with BamHI and HindIII, resulting in the removal of 
18 base pairs. Oct4 PCR product was digested with NcoI and EcoRI, resulting in the removal of 
19 base pairs. Nanog PCR product was digested with EcoRI and XhoI, resulting in the removal of 
18 base pairs. The NeuroD1 PCR product was digested with NcoI and HindIII, resulting in the 
removal of 19 base pairs. Once the had pure digested PCR product samples of Sox2, Oct4, Nanog, 
NeuroD1, and samples of pET30a_sHT vector which were then exposed to ligase and ligated with 
their specific digested pET30a_sHT vectors with kanamycin resistance gene. When the ligation 
products are obtained, they are transformed into BL21[DE3] E. coli cells and cultured in LB plates 
containing kanamycin.    
Cell colonies that are positive for the uptake of pET30a_sHT vectors containing the four 
genes and kanamycin resistance are subject to plasmid preps. The resulting plasmids are then 
digested with their specific restriction enzymes for verification of the target gene. Correctly sized 
plasmids are then subjected to DNA sequencing to confirm the identity of genes, and no mutations 
had occurred for protein expression and purification. 
2.4 High Cell-Density Bacterial Expression - Materials and Methods    
2.4.1 IPTG Induction Method  
For bacterial expression, I used the high cell-density IPTG-induction (Figure 2-3) method 





Figure 2-3: A Schematic Diagram of the High Cell-Density IPTG-Induction Method of Protein 
Expression. Cell Culture temperature and time after IPTG-induction are obtained by optimization 
of the protocol (139). 
 
This expression method uses a rich medium to achieve high cell density. We started 
bacterial expression using a rich LB medium, at 37°C. Once the cell density reaches a cell density 
that is in the middle of the growing phase before saturation, we switched the cell culture by gently 
spinning down cells and resuspending the cell pellet into the same volume of minimal M9 minimal 




and OD600 of ∼10–15 in 2xYT by using a WPA Biowave© cell density meter. Thus, bacterial cells 
are in the middle of the growing phase with a cell density of OD600 of 3–5 in LB. After switching 
the medium, we cultured bacterial cells for another 1.0–1.5 h without adding IPTG to allow the 
bacterial cells to get used to M9 minimal medium and to ensure that bacterial cells go back to the 
growth phase, at the optimized temperature that is used for the cell culture after IPTG induction. 
After this 1.0-1.5 h incubation without IPTG, the OD600 usually increases by 0.6-1.0 OD600 units. 
IPTG (1mM) was then added to induce protein production. The cell culture is incubated at the 
same optimized temperature for a period that is optimized for different proteins before cell harvest. 
We found that the OD600 value at the end of cell culture increased by 2.0- to 2.5-fold compared 
with the OD600 value at IPTG-induction. Therefore, before cell harvest, the bacterial cells can reach 
to OD600 of 6-9 with a starting medium using LB and OD600 of 8-10 using 2× YT. The cells are 
then harvested, and the protein purified (100). A schematic diagram of this protocol can be seen 
in Figure 2-3. 
2.4.2  Preparation of Starting Culture  
Starting cultures for protein expression were prepared by adding 1 µl of glycerol stock for 
each gene into LB media (Table 2-3).  These cultures were then incubated in an incubator shaker 
for ~5 hours at 37°C and 160-180 rpm.  
LB rich medium was prepared using the following recipe:  







Vitamins Kanamycin Glycerol 
Stock 





10 x LB medium stock was made using 1000 g LB powders (Invitrogen) followed by 
sterile deionized distilled water (dH2O) until 4 liters total, with an adjusted pH of 7.8. Once the 
ingredients are added, the solution is heated and stirred until the components are completely 
dissolved. The solution was poured into smaller bottles with loosened caps and autoclaved at 15 
lb/in2 for 15 min. After the bottles cool to below 40°C, the caps are tightened, and the concentrated 
LB rich medium is stored at room temperature. 
2.4.3 Protein Induction  
Once the cell density reaches a cell density that represents the middle of the growing phase 
(OD600 3-5 for LB and 5-7 for 2xYT), we switched the cell culture by gently spinning down cells 
and resuspending the pellet into the same volume of minimal M9 medium. M9 minimal medium 
was made using stock 5 x M9 salts (Table 2-5) to make the final M9 medium used in the protein 
expression and purification process (Table 2-4). After switching the medium from rich LB 
medium to minimal M9 media, we cultured bacterial cells for another 1.0–1.5 h without adding 
IPTG, at the optimized temperature to allow for the discharge of unlabeled metabolites. During 
this period, the OD600 of the cell culture should increase by 0.5-1 OD600 units. IPTG (1mM) was 
then added to induce protein production. Various IPTG concentrations and temperatures were 
tested to find the optimal values for each. The induced cultures were then incubated in the 20ºC 
shaker for ~16 hours to achieve maximum protein expression. We found that the OD600 value at 
the end of cell culture increased by 2.0- to 2.5-fold compared with the OD600 value during IPTG-
induction. 
Table 2-4: Recipe for 1-Liter M9 Minimal Medium used for Bacterial Culture Protein Expression.   
Sterile Deionized 
H2O (dH2O) 
5 x M9 Salts 
(7.8pH) 











M9 is a minimal, low osmolarity media for E. Coli, resulting in a slower growth rate of 
these cells. 5 x M9 salts were prepared by adding the following to a 2-liter flask (Figure 2-9).  
Table 2-5: Recipe for 1-Liter 5 x M9 Stock Solution used to make M9 Minimal Medium.   
1M Na2HPO4 1M KH2PO4 1M NH4Cl 1M NaCl 1M CaCl2 dH2O 
34.0 g 15.0 g 5.0 g 2.5 g 15.0 mg Top To  
1.0 L 
 
Once the ingredients are added, the solution is heated and stirred until the components are 
completely dissolved. The solution was poured into smaller bottles with loosened caps and the 
autoclave at 15 lb/in2 for 15 min. After the bottles cool to below 40°C, the caps are tightened, and 
the M9 minimal medium is stored at room temperature. 
2.4.4 Protein Purification Procedure  
 Upon completion of protein expression described above, the resulting cultures were then 
spun down by centrifugation at 8,000 rpm for 10 minutes (7,438 G) and the supernatant was 
discarded. The cell pellets were then resuspended in 1X His Binding Buffer with 6M urea (Figure 
2-9) and subjected to multiple rounds of sonication to disrupt the cell membranes while releasing 
the expressed protein into the supernatant. The sonication solutions were then centrifuged and the 
supernatant, containing the expressed protein, was applied to a column for purification.  After 
purification, the four proteins of interest are eluted from the column and subjected to dialysis to 
remove any residual salts from the purification process. The resulting protein solution was then 
freeze-dried by lyophilization to obtain pure protein powder.   
2.4.4.1 Preparation of Buffers  






Table 2-6:  Recipes for Column Protein Purification Buffers. 
1 x His-Binding 










 1440 g Urea 
 35.06 g 1M NaCl 
 400 mL 10X PBS 
 Top dH2O to 4L final 
volume 
 Adjust pH to 7.4-7.6 
 Pass through filter 
paper  
 68.08 g 
Imidazole 






 68.08 g Imidazole 
 Binding buffer to 2 L 
final volume. 
 900 mL Binding 
Buffer 
 25 mM 
Imidazole 
 150 mM NaCl 
 100 mL 0.2% 
Triton 
 1 L Binding 
Buffer 
 35 mM 
Imidazole 
 150 mM NaCl 
 
2.4.4.2 Preparation of His-tag Column  
The His-tag purification columns were prepared by the addition of ~10 ml of clean Ni-
NTA resin slurry (ThermoFisher Scientific R90110) to a clean 30 ml column.  Once silica his-
binding beads settle and form a lightly packed base, they were charged using the following our 















Table 2-7: Steps to Recharge Column for Protein Purification. 
Step Solution 
1 200 mL 0.1 M EDTA 
2 400 mL dH2O 
3 200 mL 2% SDS 
4 200 mL dH2O 
5 100 mL 1M NaOH 
6 1 L dH2O 
7 1 L dH2O 
8 1 L 1X Charge Buffer 
9 1 L 1X Charge Buffer 
10 100 mL 6 M Urea 
 
2.4.4.3 Sonication of Bacterial Cells  
To release the expressed protein from bacterial cells, the IPTG-induced bacterial cell 
cultures are spun down at 8,000 rpm for 10 minutes at the end of protein expression. The 
supernatant was discarded while the cell pellets were kept. For 1-liter of bacterial expression, the 
resulting cell pellets were then resuspended in ~30 ml 1 X His Binding Buffer/6M urea and 
subjected to three rounds of sonication to disrupt the cell membranes and release the expressed 
proteins. Each round of sonication consisted of three exposures to high power sound waves 
directed through an ultrasonic probe (ThermoFisher Scientific Sonic Dismembrator Model 500) 
for 30 seconds at a power level of 21. The supernatant was always placed back on ice for 1 minute 
between each sonication to prevent overheating that may degrade the protein. The cell pellet was 




sonication. This was repeated three times. After three sonication cycles, the cell pellets were spun 
down for 10 minutes 12,000 rpm (17,211g) and the supernatant lysate was applied to the 
purification column. A total of ~50 ml of lysate was added to each purification column. The 
solutions were applied to flow through the column at a slow pace (~1 drop per second) to allow 
the target protein to bind to the charged Ni-NTA beads. Before loading, we collected a sample of 
the lysate (100ml, Lysate), which was properly labeled. After loading the lysates on to the column, 
we also collected a flow-through sample (100ml, Flow-through), which was properly labeled. 
Both samples were placed in a -20°C freezer for SDS-PAGE.  
2.4.4.4 Column Wash  
The column was then washed with 1L 0.2% Triton-100 to remove bacterial endotoxin. A 
triton wash sample was collected and properly labeled (100 µL, Triton) for SDS-PAGE. The 
column was then washed with 1L 1X His Binding Buffer with 6M urea and 25 mM 1M imidazole 
to remove any bacterial junk proteins. These conditions were followed for each of the four 
reprogramming factors except for NeuroD1. NeuroD1 required the imidazole concentration in the 
wash to be lowered to 15 mM because the target protein would begin to elute at 20 mM. A sample 
was collected in each of the washing steps for SDS-PAGE (100 µL, Wash). All of the samples 
collected for SDS-PAGE were properly labeled and placed in a -20°C freezer for SDS-PAGE. 
2.4.4.5 Elution of Purified Proteins  
 After washing the purification column and removing the impurities, the target protein was 
eluted from the beads with 1 x His Binding Buffer/6M urea and 1M imidazole. The multiple elution 
samples were collected at different elution volume and were properly labeled (50 µl, Elution X) 
and placed in a -20°C freezer for SDS-PAGE. This elution was subjected to dialysis to remove any 




the elution was placed on a lyophilizer to obtain the pure protein powders. The protein powders 
obtained for each reprogramming gene were run on 10% SDS polyacrylamide gels to check their 
purity.  A Western Blot was then performed on each protein powder using antibodies specific to 
each protein to confirm their identity.     
2.4.5 Western Blot  
Western blot using specific antibodies was performed on each of the protein powders 
obtained to verify the identity of each protein.  I followed the western blot nitrocellulose 
membranes protocol for provided by Bio-Rad.   
The first step in the Western blotting procedure is to separate the macromolecules using 
gel electrophoresis (151).  Samples of each protein powder were dissolved in 50 µl 1X SDS loading 
buffer and placed on a 90ºC heat block for 9 minutes.  The samples were then removed from the 
heat block, allowed to cool to room temperature, and each sample was incubated with 3 µl of 
dithiothreitol (DTT) for 1 hour at room temperature to reduce any disulfide bonds. The samples 
were then used to run 10% SDS-PAGE by gel electrophoresis.  
Following separation by gel electrophoresis, the SDS-PAGE gel was transferred or blotted 
onto a 0.2 µm PVDF nitrocellulose membrane (Bio-Rad 1620097). To do this, the Nitrocellulose 
membrane is soaked in methanol because extremely hydrophobic which may hinder the movement 
of aqueous buffer and protein binding in the membrane during membrane transfer. So, PVDF 
membrane is hydrated with 100% methanol to facilitate effective transfer. Then we combine the 
SDS-PAGE gel, two pieces of filter paper, and the nitrocellulose membrane between two sponge 
pads and incubate in transfer buffer. The SDS-PAGE gel and membrane were stacked together 




block (referred to as a transfer sandwich). The transfer chamber was set to a maximum voltage of 
150. Transfer took approximately 2.5 hours to be completed in a cold room.       
Next, the membrane was incubated in 5% milk blotting blocker for 15 minutes to prevent 
nonspecific binding of antibodies to the surface of the membrane, followed by overnight 
incubation with the primary antibody at 4ºC in a cold room. The primary antibodies, an antibody 
specifically against the target protein, was diluted 1:1000 in 5% milk diluted in 1 x TBST as a 
blotting blocker. The next morning, the primary antibody was removed, and the membrane was 
subjected to four (5 minutes) washes with PBS, followed by 2-hour incubation with the secondary 
antibody at room temperature.  The secondary antibodies were diluted 1:1000 in 5% milk diluted 
in 1 x TBST. The membrane was once again subjected to four (5 minutes) washes with PBS to 
remove any excess antibody.    
Finally, the membrane was soaked with chemiluminescent substrate and enhancer in a dark 
room and the light produced by the reaction between the substrate and the enzyme conjugated to 
the secondary antibody was detected on film.  Indications of light transferred to the film verified 
the presence of the specific proteins.     
2.5 High Cell-Density Bacterial Expression – Results  
2.5.1 SDS Gel – Purification Samples  
The samples collected during protein purification of Sox2 and NeruoD1 (Pre-IPTG, Post-
IPTG, Lysate (sonication solution), Flow-through, Triton-100, Wash, and Elution X) are run on 
SDS-PAGE gel electrophoresis. Seven Samples of each of the two proteins are subject to 
centrifugation and the supernatant is discarded and, sample cell pallets are then incubated in 100 
µL 6M urea and stored in -20°C immediately after sample collections. After all, samples are 




loading buffer and placed on a 90ºC heat block for 10 minutes. The samples were then removed 
from the heat block, allowed to cool to room temperature, and each sample was incubated with 3 
µl of dithiothreitol (DTT) for 1 hour at room temperature to reduce any oligomers. The samples 
were then run on 10% SDS gels by gel electrophoresis.  
Figure 2-5 displays the results of the SDS-PAGE for each sample of the purified 
bacterially expressed reprogramming proteins. For each gel, a molecular weight marker was run 
to indicate size. In Panel A, Sox2 (34.3 kDa) is shown in the elution sample. While the predicted 
molecular weight of the Sox2 protein is 34.3 kDa and ran to a point on the gel just above halfway 
between the 34 kDa and 43 kDa indicator bands, consistent with this size. Panel B displays the 
SDS-PAGE results for the purified bacterially expressed NeuroD1 purification samples. The 
predicted molecular weight of the NeuroD1 protein is 39.9 kDa and on the gel, its elution sample 
band is displayed just above the 34 kDa indicator band, consistent with this size.  
 
Figure 2-5: SDS-PAGE of Reprogramming Protein Purification Samples. 10% SDS gel of 
purification samples for Sox2 (34.3 kDa) and, purification samples for NeuroD1 (39.9 kDa). For 
each gel, a molecular weight marker was run to indicate size; arrows indicate the position of each 
protein band; (M) is molecular weight marker, (L) is lysate or sonication solution, (T-100) is the 





2.5.2  SDS Gel – Protein Powder   
Samples of each of the two protein powders were dissolved in 50 µl 1X SDS loading buffer 
and placed on a 90ºC heat block for 10 minutes. The samples were then removed from the heat 
block, allowed to cool to room temperature, and each sample was incubated with 3 µl of 
dithiothreitol (DTT) for 1 hour at room temperature to reduce any oligomers.  The samples were 
then run on 10% SDS gels by gel electrophoresis.    
Figure 2-6 displays the results of the SDS-PAGE for each of the purified bacterially 
expressed reprogramming proteins. For each gel, a molecular weight marker was run to indicate 
size. In the right two lanes, Sox2 (34.3 kDa) is shown. While the predicted molecular weight of 
the Sox2 protein is 34.3 kDa and ran to a point on the gel just above 34kDa between the 34 kDa 
and 43kDa indicator bands, consistent with this size. Left two lanes to display the SDS-PAGE 
results for the purified bacterially expressed NeuroD1 (39.9 kDa) protein powder. The predicted 
molecular weight of the NeuroD1 protein is 39.9 kDa and on the gel, its band is displayed just 
above the 34 kDa indicator band, consistent with this size.  
 To confirm the identity of each protein powder, Western blot analysis was next carried out 







Figure 2-6: SDS-PAGE of Reprogramming Protein Powders.  For each gel, a molecular weight 
marker was run to indicate size; arrows indicate the position of each protein band.  (A) left 10% 
SDS gel of purified bacterially expressed Sox2 (34.3 kDa), (B) right 10% SDS gel of purified 
bacterially expressed NeuroD (39.9 kDa).  
  
2.5.3  Western Blot  
Western blot analysis was carried out on samples of each of the purified bacterially 
expressed reprogramming proteins to confirm their identities. Figure 2-7 shows the western blot 
results for each of the two proteins I purified, Sox2, and NeuroD1. Figure 2-8 shows the western 
blot results of SON factors. Primary antibodies specific to each protein were used to confirm the 




Figure 2-7: Western Blot Analysis Results for Sox2 and NeuroD1 Purified Recombinant Proteins 
using Anti-Sox2 and Anti-NeuroD.  
 
Anti-Sox2 Anti-Oct4 Anti-Nanog 
   
 
Figure 2-8: Western Blot Analysis Results for the Three iPSC Reprogramming Proteins. Western 
blot results for Sox2, Oct4, and NeuroD purified recombinant protein using anti-Sox2, anti-Oct4, 





2.5.4 Protein Quantification and QQ-Modification 
 After the confirmation of the identities and purity of Sox2 and NeuroD1 proteins using 
SDS-PAGE and Western Blotting, we had to finally perform QQ-reagent modification to the 
proteins to generate QQ-Sox2 and QQ-NeuroD1, so that we could apply our patented QQ-protein 
delivery technology. This was achieved by incubation of the protein: Sox2 and NeuroD1 with pre-
made QQ-reagent respectively for overnight at room temperature with slow gently shaking to mix 
well of protein and QQ-reagents. The QQ-reagent is a mixture of polyethyleneimine (PEI) and 
lipid emulsion. The final concentration of QQ-reagent was 0.2mg/ml based on PEI concentration.  
A 10% SDS-PAGE gel of QQ-Sox2 and QQ-NeuroD1 shows distinct Sox2 and NeuroD1 
bands with even more distinct QQ-reagent bands (Figure 2-9A). With this combination, the 
proteins are now referred to as QQ-Sox2 and QQ-NeuroD1. 
 In order to optimize our reprogramming protocol, the QQ-modified reprogramming 
proteins were quantified. Before quantification, reprogramming proteins were filtered using a 0.2 
µm filter for sterilization. Bovine serum albumin (BSA), a protein from bovine, or cows, was used 
as a biological protein concentration standard. BSA was purchased in crystalline. The stock BSA 
solution was diluted to span the 0.1-1 mg/mL range as shown in Table 2-8. 
Table 2-8: Standard BSA Solution Preparation. 
[BSA] µg/mL Volume (µL) of 10 
mg/mL BSA Stock 
Volume (µL) of 
MilliQ Water 
100 5 495 
200 10 490 
300 15 485 
400 20 480 
500 25 475 
600 30 470 
700 35 465 
800 40 460 
900 45 455 





Both Sox2 and NeuroD proteins and the BSA solutions were used to run a 10% SDS-
PAGE. By comparing band intensities of the target protein to the BSA, it revealed an estimated 
concentration of 0.4 mg/mL for QQ-NeuroD and 0.2 mg/mL of QQ-Sox2 (Figure 2-9 B). 
 
Figure 2-9: SDS-PAGE of QQ-modified Reprogramming Proteins, QQ-Sox2, and QQ-NeuroD1, 
with BSA Concentration Standard.   
 
A Nanodrop spectrophotometer was used to confirm our BSA protein concentration results 
of QQ-Sox2 and QQ-NeuroD1. Using Beers Law Spectrophotometry results revealed and 
confirmed a protein concentration of 0.2 mg/mL of QQ-Sox2 and 0.45 mg/mL of QQ-NeuroD. 
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2.5.5 Conclusions-Summary of Results   
  Both reprogramming proteins Sox2 and NeuroD1 were bacterially expressed in E. coli 
using the high cell density IPTG-induction method. The bacterial cultures were then sonicated, 
and the expressed protein was subsequently purified using a His-tag column. Washing the column 
allowed us to remove most of the impurities to obtain purified proteins of interest. The proteins 
were then eluted from the column and subjected to dialysis to remove the salts that resulted from 
the purification process. The eluted protein solutions after dialysis were then freeze-dried on a 
lyophilized to obtain pure protein powders. The protein powders were then run on 10% SDS-
PAGE and the size and purity of each protein were confirmed. The identity of each of the protein 
powders confirmed using Western blot analysis. The proteins were then QQ-reagent modified to 
generate QQ-Sox2 and QQ-NeuroD1 and quantified using BSA as a concentration standard and 
Nanodrop spectrophotometry. With the above procedure, we have successfully produced QQ-Sox2 
and QQ-NeuroD1 proteins, ready for our cell reprogramming experiment of human fibroblast into 
iNSCs. 
2.6  Discussion  
Our laboratory previously has successfully sub-cloned the genes of my two reprogramming 
proteins: Sox2, and NeuroD1 into the pET30a_sHT expression vector, allowing me to perform 
bacterial expression of the proteins using BL-21[DE3] E. coli cells. Through rounds of successful 
protein bacterial expression and column purification, over 60 mg of pure protein powder was 
obtained for both proteins whose identities were confirmed by Western blot analysis. After 
numerous rounds of protein purification, I was able to isolate high-quality Sox2 and NeuroD1 




Throughout the duration of these experiments, I was able to acquire effective experimental 
skills. I have learned how to perform protein expression and purification, SDS-PAGE 
electrophoresis, and Western Blotting at an advanced level. These molecular biology skills will 
certainly allow me to repeat these protocols in future experiments and, perform troubleshooting, 
and optimize conditions when problems arise. Now, I’m also able to review literature at a more 
skilled level than when I began in 2018. I have also learned how to effectively communicate, 
collaborate, and report findings much more clearly and applicably. Most importantly, I have 
intensified my skill of working independently in the lab through the organization, multitasking, 
problem solving, and budgeting time. All these experiences have given me a strong self-disciplined 













CHAPTER 3: GENERATION AND CHARACTERIZATION OF PROTIEN INDUCAED 
NEURAL STEM CELLS (pi-NSCs)  
3.1 Goal  
The goal of this chapter was to apply a protein-induced pluripotency stem cell (piPSC) 
technology developed in Dr. Wang’s laboratory (Patents) to produce safe, high quality, and 
homogeneous protein-induced neural stem cells (piNSCs) from neonatal human dermal fibroblast 
cells (HDFn). The current reprogramming technology uses viral-gene delivery techniques that 
suffer from imperative challenges such as low efficiency, time-consuming, complicated, 
expensive, and major safety concerns. These reprogramming methods often show a conversion 
efficiency of 0.01% (5). The reprogramming procedure developed in Dr. Wang’s laboratory 
includes a simple incubation step of somatic fibroblast cells with the bacterially expressed 
transcription factors in media to achieve piPSC generation within 10-days with near 90% 
conversion efficiency (134). We applied this reprogramming procedure to generate piNSCs within 
1-2 weeks, followed by differentiation of the generated piNSCs into astrocytes, oligodendrocytes, 
and neurons within two weeks.   
Our reprogramming procedure utilizes a QQ-protein delivery technology, a high yield 
bacterial expression protocol, and an in-cell protein refolding system. The QQ-protein delivery 
technology delivers reprogramming proteins to cross the cell membrane and enter into the nuclei 
of somatic fibroblast cells (137). Based on localization signal sequences carried by the 
reprogramming proteins, this technology also allows us to deliver these proteins to the nucleus so 
that these transcription factors can interact with the promoter and repressors of different genes on 
the chromosome to regulate cell fate changes. Lastly, the QQ-reagent also protects the 




Furthermore, a low cost and high yield bacterial expression protocol, allowed us to produce 
over 60 mg of recombinant Sox2 and NeuroD1 proteins. To ensure that our reprogramming 
proteins were properly folded, we utilized an in-cell protein refolding technique developed in our 
laboratory (152), allowing the intracellular protein folding machinery to efficiently refold the 
proteins that are directly delivered into the correct intracellular compartment of the HDFn cells 
(137). The folded proteins are then targeted to the cell nuclei to initiate cell reprogramming of 
HDFn.        
Chapter 2 outlines the subcloning and protein expression and purification of two 
reprogramming proteins Sox2 and NeuroD1; resulting in the production of at least 60 mg pure 
protein for each reprogramming proteins. This chapter will discuss the QQ-modification and 
delivery of these proteins into HDFn, protein-induced cell reprogramming to generate piNSCs, 
characterization of the generated, as well as differentiation of the piNSCs into neural tri-lineage 
cells including astrocytes, oligodendrocytes, and neurons.  
Previous studies have used various reprogram cocktails, with different combinations of the 
transcription factors, in the reprogramming experiments to generate iPSCs. The cocktails included 
the combinations of the traditional Yamanaka factors (Oct4, Sox2, Klf4, and cMyc), as well as 
other combinations with new factors (Oct4, Sox2, Nanog and Lin28; Oct4, Sox2, and Nanog; Oct4 
and Nanog; Nanog only) to induce iPSCs. A study has also found that only a single factor is enough 
to reprogram HDFn into the neural linage (29). One of our goals is to examine new combinations 
of transcription factors that allows us to eliminate oncoproteins and to provide safer piNSCs for 




3.2 Characterization of piNSCs  
 In order to confirm that reprogrammed cells are multipotent, the generated piNSCs need 
to be fully characterized. To achieve this goal, we used the visualization of morphology and colony 
formation under the microscope and immunostaining techniques.  
Neural stem cells give rise to all three neural lineages, have a capacity to self-renew (153). 
In vitro differentiation is the induced differentiation of piNSCs in the neural differentiation 
medium. Typically, this process involves the formation of neurons, and glia. The successful 
differentiation of these cell types indicates that the cells have the developmental potential of 
multipotent NSCs. 
The visualization of morphology and colony formation under the microscope is commonly 
used as the initial form of characterization during cell reprogramming of HDFn into piNSCs. NSCs 
proliferate in neurosphere-like structures which can differentiate into complex astrocytes, 
oligodendrocytes, and neurons (68). Astrocytes display heterogeneous fibrous morphologies and 
are the most abundant glial cells in the central nervous system (CNS) and participate in synaptic, 
circuit, and behavioral functions (154). Oligodendrocytes display highly complex structures with 
extraordinary large myelin sheath extensions out of the cell membrane (155). Neurons display a 
con-like cell body called the soma, a long thin axon, and numbers and dimensions of axonal and 
dendritic branches (160). These cells, especially piNSCs, are distinct from the spindle-shaped 
fibroblast cells.  The observation of typical NSC, neuron, and glia cell morphology, the ability of 
piNSCs cells to form colonies, and quick reprogramming time serve as good indicators that the 
reprogramming protocol has been successful. However, these cells must face more rigorous 




Immunostaining for common NSC, neuron, and glia markers provides further confirmation 
of successfully induced multipotency of piNSCs and their differentiation. Immunostaining 
includes the use of fluorescently labeled antibodies to detect the presence of particular proteins 
inside cells.  The detection of common proteins in these desired cells indicates a switch from a 
somatic transcriptional network to that of a multipotent NSC.    
Quantitative reverse-transcription PCR (qRT-PCR) is a technique that is used to measure 
the level of expression of a target gene (mRNA) (126). This is done by combining the reverse 
transcription of mRNA with PCR amplification (126). PCR is technically another method to find 
neural progenitor markers, serving as another indication that the cells have changed from somatic 
cell gene expression patterns to NSC, neuron, and glial gene expression patterns. This technique 
also serves as a method to compare gene expression patterns in different cell types, including 
induced and wildtype. We originally plan to perform qRT-PCR to our piNSCs samples as well as 
the samples of the induced differentiation of piNSCs into neurons, astrocytes, and 
oligodendrocytes, however, due to the Covid-19 pandemic, we could not complete these 
experiments.   
Electrophysiology is to study the electrical properties of biological cells and tissues. 
Neurons exhibit electrophysiological properties. Functional neurons derived from piNSCs, under 
the conditions of primary neuron culture, express synapsin, suggesting synaptic formation in vitro 
(29). A patch-clamp technique is a technique in electrophysiology to show electric currents of an 
individual cell, tissues, or different areas of a cell’s membrane. Testing different areas of one cell 
membrane is referred to as, whole-cell patch-clamp with voltage-clamps and current-clamps. 
Voltage clamp recordings of mouse iNCS-derived neurons revealed hyperpolarized resting 




mode can elicit action potentials by depolarizing the membrane (29). Therefore, neurons derived 
from piNSCs shall exhibit the functional membrane properties of wildtype neurons. Due to the 
lack of technical expertise and equipment, we did not plan to perform patch-clamp experiment. 
The formation of complex organs depends on precise spatial and temporal controls of gene 
expression (156). Therefore, epigenetic mechanisms have been frequently attributed to playing a 
central role in controlling cell fate determination (156).  DNA demethylation analysis is an 
epigenetic marker to confirm if this gene is activated for expression. DNA methylation 
immunoprecipitation followed by microarray analysis of piNSCs can visually show the differences 
between all types of cells used in this experiment. We did not plan to perform DNA demethylation 
analysis of our piNSCs. 
Reynolds and Weiss demonstrated the presence of NSCs in mouse brain by employing a 
novel serum-free culture system termed the neurosphere assay (58). Neurosphere assay is a culture 
system with floating clusters of NSCs and provides a method to investigate neural precursor cells 
in vitro. This is achieved by suspending NSCs in medium with growth factors that lacks adherent 
substrates. This method allows NSCs to form into clusters that contain a small percentage of NSCs 
(158). Neurosphere assay focuses on three imperative characteristics of neural stem cells: self-
renewal, proliferation, and multipotency (158). This method is beneficial because it shows the 
ability of iNSCs to integrate themselves into host CNS without disrupting normal function.  
In vivo differentiation is a more stringent method for determining the developmental 
potential of iNSC. To examine the in vivo developmental potential of iNSCs, researchers 
transplanted iNSCs into the brains of neonatal myelin-deficient (md) rats (68). Two weeks after 
transplantation, they could detect murine neural marker M2 and oligodendroglia proteolipid 




study revealed that the implanted iNSCs might be differentiated into M2-positive cells with 
astrocyte morphology in a variety of host brain regions including cortex and striatum. Many of the 
M2-positive profiles could be double immunostained with an antibody against GFAP. While these 
data need to be complemented by other glial markers and an assessment of in vivo neuronal 
differentiation, they clearly demonstrated that iNSCs survive and give rise to differentiated neural 
cells in vivo, which makes this method highly beneficial (68). 
For this thesis, we examined the morphology of the generated piNSCs as well as the 
differentiated neurons, astrocytes, and oligodendrocytes under a light microscope and performed 
immunostaining to detect various markers of piNSCs and their differentiated neurons, astrocytes, 
and oligodendrocytes.  We also cultured piNSCs for an extended period (2-3 months) to show their 
ability of long-term self-renewal and proliferation. Furthermore, we performed in vitro 
differentiation assays and staining to show the development of potential neurons and glial cells.  
3.3  Generation and Characterization of piNSCs - Materials and Methods  
3.3.1  Preparation of Starting Cells  
Human neonatal dermal fibroblasts (HDFn) were purchased from ThermoFisher.  These 
cells were plated onto gelatin-coated tissue culture plates in DMEM medium with 10% FBS 
containing antibiotics to reduce the risk of infection.  HDFn were incubated in a 37ºC (5% CO2) 
incubator and the medium was changed as needed until their growth reached approximately 50-
70% confluence.   
3.3.2  QQ-Protein Delivery Method  
To deliver the reprogramming proteins into the cells, we used QQ-protein delivery 
technology developed in our lab (137, 138, 152).  The QQ-reagent efficiently delivers the protein 




to be targeted to the specific intracellular compartment based on the localization signal sequence 
carried by the specific protein (137, 138, 152).    
The process of QQ-modification of the proteins consisted of a simple overnight incubation 
of the reprogramming proteins with the QQ-reagent, a polyethyleneimine (PEI), and lipid 
emulsion. A stock solution of the QQ-reagent (molecular weight 1,300) was prepared in 50 mM 
NaPi buffer at 25 mg/ml at pH 7.4.  Approximately 1 mg of each of the reprogramming proteins 
was dissolved in the same concentration of NaPi, resulting in protein concentrations between 0.5 
mg/ml and 1 mg/ml. The exact protein concentration for each of the reprogramming proteins was 
determined by electrophoresis with BSA as a concentration standard and confirmed by nanodrop 
spectrophotometry following QQ modification. The protein was mixed with QQ-reagent, drop by 
drop, and incubated in at 4 ºC overnight. The final concentration of QQ-reagent in the QQ-protein 
was 0.1mg/ml. The following day, the QQ-modified protein solutions were centrifuged at high 
speed to remove any precipitate that resulted from the modification process. The supernatant was 
removed from the precipitate if there was any and directly used for cell reprogramming; no further 
purification was needed. The QQ-modified reprogramming proteins were then mixed in DMEM 
medium at specific concentrations to make reprogramming medium.  
For protein-induced cell reprogramming, the delivered reprogramming proteins need to 
enter the nuclei of cells to bind to different DNA promoters and repressors. The reprogramming 
proteins bind to the repressors of somatic differentiation genes to silent their expression, as well 
as bind to the promoter’s neural multipotent genes to activate their gene expression to initiate cell 
reprogramming (10). Using a fluorescence microscope, we showed that QQ-modified 
reprogramming protein, Sox2, reached to the nucleus of the majority cells within a few hours of 




cells since imaging was performed during the protein delivery cycle and the proteins were in the 
dynamic process of reaching the nuclei via the cytosol after being delivered across the plasma 
membrane.  
 
Figure 3-1:  Fluorescence Images of the Nuclear Targeting of the QQ-delivered Reprogramming 
Protein Sox2. Immunostaining results for Sox2 3-5 hours after protein delivery through incubation 
with HDFn. (Top) DAPI nuclear stain. (Bottom) Sox2 shown in Green.  
  
3.3.3 piNSC Reprogramming Protocol  
Our reprogramming protocol is a straightforward protocol that includes the preparation of 
bacterially expressed proteins, quantification, QQ-modification, and 8-14 cycles of cell 
reprogramming (Figure 3-2). Each cycle is applied in the growth medium or 5-16 hours per cycle. 
The optimized protocol for HDFn cells begins with tree cycles of incubation with QQ-SON factors. 
Each cycle is followed by incubation with regular medium for 24 hours with no QQ-modified 
proteins within freshly replaced growth medium. The three QQ-SON cycles allow the fibroblasts 
to be driven into a transient pluripotent state (4 Days for HDFn to iPSC-like state). This is then 
followed neuronal differentiation cycles of QQ-Sox2 and QQ-NeuroD1. QQ-Sox2 (3 cycles, 4-8 




neuronal differentiation of our iNSCs into astrocytes, oligodendrocytes, neurons. An optimized 
protein concentration of 0.1 µg/ml was used for all proteins. 
The cells are incubated in regular cell culture medium (10% FBS) so that they could grow 
and become confluent in the dish throughout the QQ-SON induction. Once the cells reached 80-
90% confluence and have developed into a transient pluripotent state cell, the entire dish was 
passaged, 50% to a new dish, and the remaining 50% was kept in the original dish. With the 
application of QQ-Sox2, the cells are incubated in NSC medium, and with the application of QQ-
NeuroD1 the cells are incubated in NSC differentiation medium. In all, Throughout the 
reprogramming process, media is switched between cycles, beginning with regular media, then 
NSC medium, and finally differentiation media. Continuous passaging was performed along with 
the medium alterations yields differentiated astrocytes, oligodendrocytes, and neurons within 19-
22 days after QQ-SON induction of HDFn (Figure 3-2). 
Figure 3-2: Schematic Diagram of the Reprogramming Protocol; including Three Different 
Reprogramming Cycles of QQ-SON, QQ-Sox2, and QQ-NeuroD. Involving a few rounds of 5-16 




3.3.4 Characterization of piNSCs, Neurons and Glial Cells 
Numerous methods are available today to characterize piNSCs and determine if they are 
fully reprogrammed into a multipotent state. These characterization techniques assess the 
similarities between the generated piNSCs and naturally occurring NSCs.  The following 
characterization techniques were utilized in these reprogramming experiments to determine the 
success of each: visualization of morphology under the microscope, immunostain for multipotency 
markers, and immunostain for in vitro differentiation.   
3.3.4.1 Visualization of Morphology  
The morphology of each of the reprogramming experiments was visualized by examination 
under a light microscope as the initial measure for the success of the reprogram. NSCs display 
proliferates in neurosphere-like structures which can differentiate into complex astrocytes, 
oligodendrocytes, and neurons (153, 142). Astrocytes display heterogeneous fibrous morphologies 
and are the most abundant glial cells in the central nervous system (CNS) and participate in 
synaptic, circuit, and behavioral functions (154). Oligodendrocytes display highly complex 
structures with extraordinary large myelin sheath extensions out of the cell membrane (155). 
Neurons display a cell body called the soma, a long thin axon, and numbers and dimensions of 
axonal and dendritic branches (159).   These cells are distinct from the spindle-shaped fibroblast 
cells that are commonly used as the parental cell in reprogramming experiments.    
3.3.4.2 Immunostaining for NSC Markers  
 Immunostain using specific antibodies was carried out on the final piNSCs of each 
reprogramming to detect the common NSC markers for an indication of successful 
reprogramming. The iNSCs were examined for the nuclear markers, Sox2, Pax6 as well as the 




attached to and incubated in the 37ºC CO2 incubator. The cell culture medium was then removed, 
and the cells were washed twice with PBS for 5 minutes each time. For fixation, the cells were 
treated with 10% formalin for ~10 minutes at room temperature.  The fixed cells were then washed 
3 times with 1 x PBS for 5 minutes each time.  Next, the cells were treated with a penetration 
buffer, consisting of 0.2% Triton-100, and 0.2% BSA for 2 hours at room temperature to allow the 
entrance of the specific antibodies into the cells. The cells were then incubated overnight (~16 
hours) at 4ºC with the primary antibody. Anti-Sox2 (1:300, Invitrogen), anti-Pax6 (1:300, 
Invitrogen), and anti-Nestin (1:300, Invitrogen) were used.  The cells were then washed 3 times 
with the wash buffer and then incubated with the secondary antibody, which is fluorescently 
labeled for 2 hours at room temperature.  Alexa Fluro mouse anti-rabbit IgG (1:2000, Invitrogen), 
Alexa Fluro goat anti-mouse IgG (1:2000, Invitrogen), and Alexa Fluro rabbit anti-mouse IgM 
(1:2000, Invitrogen) were used.  Following a final round of 3 washes with the wash buffer, the 
cells were mounted with medium containing DAPI (1:5000, Invitrogen) to stain for the nucleus, 
the slides were taken to the microscope imaging system for viewing of florescence. As negative 
controls, the starting HDFn cells were also performed using the same immunostain procedure.  
3.3.4.3 In Vitro Differentiation   
In order to examine the developmental potential of piNSCs, the in vitro differentiation was 
performed. The generated piNSCs were passaged to 12-well culture plates and incubated in NSC 
medium (DMEM contain: 10% FBS, bFGF 20ng/ml, 0.1 mM non-essential amino acid, 2 mM L-
glutamine) for 3 weeks in the 37ºC CO2 incubator. The Medium was changed as needed. The 
generated piNSCs were also cultured in a special NSC differentiation medium (DMEM contain: 
2-5% FBS, BFGF 10ng/ml, EFGF 10ng/ml, 0.1 mM non-essential amino acid, 2 mM L-glutamine) 




various cell types was observed under the microscope through changes in cell morphology and 
was confirmed by immunostaining for specific cell markers: Tuj1 and ChAT for neurons, GFAP 
for astrocytes and O4 for oligodendrocytes.  
3.3.4.4 Culture of piNSCs - Long-Term Self-Renewal  
The reprogrammed cells were dissociated as a single cell suspension using trypsin (0.05%) 
and transferred onto new wells with NSC medium containing 1X DMEM (ThermoScientific, 
11885084) with 0.1 mM Nonessential amino acid (ThermoScientific Gibco, 11140050), 2 mM 
L-glutamine (ThermoScientific Gibco, 25030081), 2% FBS (ThermoScientific Gibco, 
16000044), 20 ng/mL bFGF (ThermoScientific Gibco, PHG0360). Many neurospheres were 
observed during self-renewal. The cells were passaged every 5 – 8 days when the dish was 80-
90% confluent and were cultured for over 10 passages for 2 months. The medium was prepared 
fresh medium every other week and kept this medium in a cold room (4°C). 
3.4 Generation and Characterization of piNSCs - Results  
3.4.1 Morphology Change During Reprogramming   
NSCs display proliferation in neurosphere-like structures that can differentiate into 
complex astrocytes, oligodendrocytes, and neurons. The piNSCs generated by the use of our 
reprogramming cocktail displayed NSC-like morphology (Figure 3-3).  The reprogramming 
cocktail includes QQ-SON, and QQ-NeuroD1, and QQ-Sox2. The neurospheres pictured in 
Figure 3-3 resulted within the first week after whole dish passaging. For each reprogramming 
cocktail, a large number of NSC-like cells with neurosphere morphology was observed at about 







Figure 3-3: Pictures of piNSC Neurospheres Resulting from QQ-SON, and QQ-Sox2 
Reprogramming Cocktail. (A) Untreated human dermal neonatal fibroblasts (HDFn) are shown as 
a negative control. (B-F) Neurospheres. (B) Day 3. (C) Day 5. (D) Day 8. (E) Day 10. (F) Day 13.  
  
3.4.2 Immunostaining for the Reprogrammed Cells 
Immunostains were carried to detect the NSC markers: Sox2, Pax6, and Nestin. 
Identification of these markers inside piNSCs provides an indication of the reprogramming of 
unipotent fibroblast cells to multipotent piNSCs. To estimate conversion efficiency, we 
intentionally prepared monolayer cells for these immunostains. As a negative control, the same 
immunostains were performed using HDFn with the same multipotency markers and these starting 
HDFn showed negative stains. 
3.4.2.1 Immunostaining for Neural Stem Cells  
Immunostaining for the nuclear multipotency markers Sox2, Pax6, and Nestin were carried 
out on the piNSCs generated using QQ-SON and QQ-Sox2 only (Figure 3-4). Staining was 
performed following the sixth passage after reprogramming.  In Figure 3-4, blue DAPI stain was 




the presence of Pax6 is indicated by red fluorescence. Sox2 and Pax6 must be visible inside of the 
nucleus of the cell because they are transcription factors with the blue DAPI stain for the nuclei. 
Co-staining indicated the cell was positive. Nestin is an intermediate filament involved in the radial 
growth of axons, and is its stain shows through the cell and not limited to areas like Sox2 and Pax6 
which are localized to the nucleus. A large percentage of positive cells were identified. 
 
Figure 3-4: Fluorescence Images of Single Immunostains for NSC Markers Sox2, Nestin, and 
Pax6.  All cells were in the 6th passage after reprogramming cycles. (A) Nestin is indicated by 
green. (B) Negative control of Nestin. (C) Pax6 indicated in red. (D) Negative control of Pax6. (E) 
Sox2 is indicated in green. (F) Negative control of Sox2. Blue DAPI stain was used to indicate the 
nuclei of cells.  Negative controls are starting HDFn cells.  
 
3.4.2.2 Cell Conversion Efficiency of iNSCs   
 The conversion efficiency to iNSCs from HDFn using a reprogramming protocol, 
including cell reprogramming using QQ-Sox2, QQ-Oct4, and QQ-Nanog (QQ-SON) for three 
cycles, followed by the guided neural differentiation using QQ-Sox2 alone, has been determined 
based on immunostain data (Table 3-1). The immunostain data of markers Sox2, Pax6, Nestin, 




were counted to determine the percentage of iNSCs. The percentages for each of the markers were 
then averaged to determine a percentage for the overall efficiency of reprogramming. 
Table 3-1 displays the results of the conversion efficiency analysis. As indicated in the 
table, each of the four NSC markers indicated high cell conversion efficiencies about 80% using 
the reprogramming protocol described above. While each of the NSC markers shows very similar 
efficiencies, the average conversion efficiency is 78.8±4. While the NSC conversion efficiency 
of the currently published literature is only ranged 0.1-0.5%, our conversion efficiency of the 
piNSCs using this described reprogramming protocol above is extremely high. 
Table 3-1:  Efficiency of Reprogramming.  For the generation of NSCs of the reprogramming 
cocktail of QQ-SON followed by QQ-Sox2 alone. Average reprogramming efficiency determined 
based on the percentage of cells that stained positive for the multipotency markers Tuj1, Sox2, 
Pax6, and Nestin.   







3.4.3 In Vitro Differentiation of NSCs   
To examine the developmental potential of piNSCs, in vitro differentiation was performed. 
When piNSCs were subjected to a neural differentiation medium that contained QQ-NeuroD, they 
readily differentiated into various neural-linage restricted subtypes. Figure 3-5A shows the 
pictures that indicate the morphology of undifferentiated piNSCs that have been generated using 
a reprogramming protocol of the two separate cycle sets of QQ-SON, and QQ-Sox2 alone as 
described above in Figure 3.2. Differentiation was carried out by incubation with the 
differentiation medium for 14 days using the fifth passage of piNSCs.  Pictures of control HNFs 




non-differentiated piNSCs, showed very different morphologies as compared to the differentiated 
neural-lineage cells, which show morphologies of neural-like outgrowths.    
Differentiation of piNSCs was further confirmed by visualization of morphology. When 
piNSCs were incubated with special NSC differentiation medium they readily differentiated into 
astrocytes, oligodendrocytes, and neurons (Figure 3-5).  These results indicated that the piNSCs 
generated have the developmental potential to develop into various cell types, aided in the visual 
confirmation of their multipotency.    
 
Figure 3-5:  Morphology of HDFn, piNSCs and the Differentiated piNSCs. (A) Morphology of 
the starting HDFn. (B) Morphology of the generated piNSCs. (C-F) Morphologies of the 
differentiated neural-lineage restricted cells. (C, D) Neuronal-like morphology. (E) Astrocyte-like 
morphology. (F) Oligodendrocyte-like morphology. Long neuronlike extensions are indicated by 
arrows.    
 
3.4.3.1 Immunostaining for Neurons  
Immunostain for immature and mature neurons was carried out on cells that have been 
induced differentiated into neural tri-lineage cells in a medium that contained QQ-NeuroD1 




QQ-NeuroD1-induced differentiation cycle. In Figure 3-6, blue DAPI stain was used to label the 
nuclei of cells. For TUJ 1 (Figure 3-6 A-D), NSE (Figure 3-6 E-F), and ChAT (Figure 3-6 I-L) 
stains are distributed throughout the cells. A large percentage of positive cells were identified after 
our reprogramming protocol versus HDFn controls with significant visual differences. The 
expression of these immature (Tuj1) and mature neuron markers provides strong indication of 
successful reprogramming.  
 
Figure 3-6: Fluorescence Images of Single and Double Immunostain for Neuronal Markers TUJ1, 
NSE, and ChAT.  All cells were in the third passage after QQ-SON, QQ-Sox2, and QQ-NeuroD 
reprogramming cycles. (A, B, C) Tuj1 shown in green. (D) Negative control for Tuj1 immunostain. 
(E, F) NSE shown in red. (G) NSE shown in green. (H) Negative control for NSE immunostain. 
(I, J, K) ChAT shown in green. (L) Negative control for ChAT. (F, J) Double immunostain of 
NSE in red and ChAT in green. Negative controls of immunostains using starting HDFn. Blue 
DAPI stain was used to indicate the nuclei of cells.  
 
3.4.3.2 Immunostaining for Astrocytes and Oligodendrocytes   
Immunostaining for astrocytes and oligodendrocytes was carried out on cells that have 
been induced differentiated into neural tri-lineage cells in a medium that contained QQ-NeuroD1 




after the last QQ-NeuroD1-induced differentiation cycle. Immunostain for the astrocyte marker 
GFAP, and the oligodendrocyte marker O4 were carried out on the differentiated cells and control 
cells (Figure 3-7).  Blue DAPI stain was used to label the nuclei of cells.  The presence of O4 is 
indicated by red fluorescence (Figure 3-7 F-H), while the presence of GFAP is indicated by green 
fluorescence (Figure 3-7 I-J). O4 and GFAP are visible throughout the cells in order to be 
considered positive. A large percentage of positive cells were identified, which provides a strong 
indication of successful differentiation of the piNSCs into astrocytes and oligodendrocytes. Phase-
contrast images are displayed directly about immunostains (Figure 3-7 A-E). Negative controls 
are also stained with O4 and GFAP markers to show unexpressed biomarkers in HDFn (Figure 3-




Figure 3-7: Fluorescence Images of Single Immunostain for Astrocytes (GFAP) and 
Oligodendrocytes (O4). All cells were in the third passage after the QQ-NeuroD1-induced 




in red. (I-J) GFAP shown in green. (K-L) Negative controls of immunostains using starting HDFn. 
Blue DAPI stain was used to indicate the nuclei of cells.   
 
3.4.4 Conclusions-Summary of Results   
In this chapter, we investigated the generation and characterization of multipotent NSCs 
with NSC properties from human fibroblasts using three reprogramming factors (QQ-Sox2, QQ-
Oct4, QQ-Nanog). The conversion efficiency of piNSC generation from fibroblasts in this 
experiment was 78% as determined from positive immunostaining results for NSC biomarkers 
(Nestin, Pax6, and Sox2). Continuous whole-dish passaging of human reprogrammed cells showed 
self-renewal capacity in the presence of growth factors, reprogramming factors, and suitable 
medium. piNSCs were also stably expanded for over 10 generations in a feeder-free culture system 
for 2 months. These piNSCs formed NSC-like neurospheres.  
piNSCs Displayed tri-lineage developmental potential through in vitro differentiation 
Immunostaining experiments using QQ-NeuroD1 alone. The expanded piNSCs readily 
differentiated into various neural-linage restricted cell types such as neurons, astrocytes, and 
oligodendrocytes. Characterization of piNSC tri-lineage differentiation capacity was investigated 
using visual analysis of morphology and immunostaining for specific lineage biomarkers (Tuj1, 
ChAT, NSE, O4, and GFAP). ChAT and NSE stain for neurons, GFAP for astrocytes and, O4 for 
oligodendrocytes.    
3.5 Discussion  
The transplantation of neurogenic precursors into the CNS for protection and 
neurodegeneration in humans with injury or disease has not achieved widespread testing and 
implementation. NSCs serve as a tool for studying neural development and neurological disorders 
(57). The ability to isolate NSCs is very difficult, and currently, no methods have been well-




ability to induce NSCs from abundant somatic cells eliminates the controversy of using human 
embryos to derive stem cells.   
Like NSCs, human iNSCs can undergo unlimited self-renewal, proliferation, and are 
multipotent cells that are capable to differentiate into neurons and glia. However, unlike NSCs, 
iNSCs can be derived from a patient’s own somatic cells, evading the risk of immunologic 
rejection for in patient-specific therapies (39). iNSCs, therefore, display the potential to be utilized 
in a broad range of applications such as cell replacement therapy for regenerative medicine, 
pathology of neurodegenerative disease in a dish, and research of toxicity and drug discovery for 
neurodegenerative disease, without the controversy and difficult isolation involved with using 
human NSCs (29).  
While work has been accomplished in developing iNSCs, the current techniques cause cell 
reprogramming to be a random process, obstructing the study of reprogramming and the 
applications for iNSCs. Gene delivery methods for iNSC generation are time-consuming, low 
efficiency, and unsafe for clinical applications due to the high risk of genetic mutations.  The 
current protein-delivery techniques use the CPP-fused reprogramming proteins, which are not 
metabolically stable and do not possess nuclear targeting capability (120, 121). In addition, these 
reprogramming protocols require the delivery of high concentrations of protein furthering the 
expenses required for reprogramming cells. 
The reprogramming highlighted in this thesis reprograms somatic cells through the direct 
delivery of reprogramming proteins, which evades the safety risks associated with the gene-
delivery methods. Our lab has developed an efficient QQ-protein delivery technology, to solve the 
technological challenges faced by the current protein delivery technology. Our lab has also 




proteins. This was followed by an in vivo refolding protocol which, after QQ-delivery of the 
proteins, employed mammalian cell machinery to properly refold the proteins. The QQ-protein 
delivery technology allowed us to efficiently deliver reprogramming proteins across the cell 
membrane and into the cytoplasm (137, 138, 152).  The QQ reagent non-covalently binds to the 
delivered proteins and protects them from degradation by intracellular proteases. This ensures that 
the delivered proteins refold into their native form and possess the metabolic stability to carry out 
reprogramming (137). QQ-delivered proteins can specifically localize in the targeted intracellular 
compartments based on their sequence localization signals (137). Once the delivered 
reprogramming proteins were properly refolded, they were targeted to the nucleus where they 
carried out their functions as transcription factors.  
Using this protocol, we have successfully generated piNSCs through incubation of HDFn 
with QQ-modified SON (3 cycles, 5 hours each cycle) in 10% FBS medium and QQ-modified 
Sox2 alone (4 cycles, 16-24 hours each cycle) in NSC medium. We further differentiated the 
generated piNSCs to neurons, astrocytes, and oligodendrocytes under the differentiation medium 
that contained QQ-NeuroD1 protein (4 cycles, 16-24 hours each cycle).   
Following a whole-dish passaging method, the piNSCs formed neurospheres. These 
piNSCs were stably and homogenously expanded for 2 months. Characterization of piNSCs by 
immunostaining to confirm the expression of NSC makers. An In-depth analysis of 
immunostaining data verified high cell conversion efficiencies about 80%. 
Further characterization of piNSCs by in vitro differentiation confirmed the developmental 
potential and multipotency of these piNSCs. Characterization of the multipotency of piNSCs was 




Our method uses a tightly controlled induction by IPTG and utilizes both rich and minimal 
media to achieve a very high cell density for the production of recombinant proteins.  This method 
obtained a much higher yield of recombinant proteins than the bacterial expression system or the 
human cell expression system employed by the other groups (120, 121).  Our high-efficiency 
bacterial expression method can reduce the cost of reprogramming 
Our reprogramming technology offers an efficient and fast method to generate human 
piNSCs that are safe for potential human clinical applications. This technology directly delivers 
bacterially expressed proteins for cell reprogramming, making this method simple and inexpensive 
(134). The speed at which piNSCs are achieved with this protocol will allow for the affordable 
generation of patient-specific piNSCs for transplantation. Previously used methods show very low 
iNSC conversion efficiencies (0.001-0.01%) versus our QQ-protein delivery technology which 
displayed high piNSC conversion efficiency (78%).  
Furthermore, our reprogramming technology features an in vivo protein refolding 
mechanism that enables direct delivery of bacterially expressed protein to the correct mammalian 
intracellular compartment for intracellular refolding machinery to efficiently refold the proteins. 
This in vivo refolding technology reduces cost when compared to previously used in vitro methods 
because in vitro protein refolding protocols require an additional purification step that is 
inefficient, making the reprogramming proteins expensive (120). QQ-modification of the protein 
also protects the delivered proteins form degradation by intracellular proteases, which reduces the 
frequency and quantity needed to reprogram fibroblasts to piNSCs.  
In all, piNSCs from human dermal fibroblasts using QQ-SON pluripotent reprogramming 
as a tool to quickly reset the time clock of the human somatic fibroblasts to a transient pluripotent 




our patented QQ-protein delivery technology. The generated piNSCs rely on endogenous gene 
expression of the NSC factors to express NSC markers and resemble wild-type NSCs in their 
morphology, self-renewal, and gene expression profiles. Furthermore, the generated piNSCs 
indicate multipotency with the capability of differentiating into neurons, astrocytes, and 
oligodendrocytes, as confirmed by the cell morphology and their specific biomarker protein 
expressions. Thus, self-renewable and multipotent piNSCs without tumorigenic potential can be 
generated from fibroblasts by our method. 
3.6 Future Directions  
The generation of clinically safe piNSCs presents a great opportunity to the scientific and 
medical communities. Further investigation may be done to elucidate the mechanism of 
reprogramming as well as the potential applications of these cells. Specifically, I would like to 
apply transcriptomic technologies to study the transcriptome of the induced cells, the sum of all 
the RNA transcripts, and compare to naturally occurring neurogenic cells. Other characterization 
experiments such as DNA demethylation analysis, karyotyping, and qRT-PCR could further show 
the presence of neurogenic markers. Furthermore, studies should be employed to examine various 
reprogramming cocktails and reprogramming technologies to determine which achieve the highest 
quality neurogenic cells. These experiments will clarify the molecular mechanisms of 
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The generation of induced neural stem cells (iNSCs) and induced neuronal cells (iNCs) 
from somatic cells provides new avenues for basic research and potential transplantation therapies 
for neurological diseases. However, clinical applications must consider the tumor formation 
capabilities of the implanted cells, the inability of iNCs to self-renew in culture, and 
reprogramming methods that use retroviral transduction which permanently alter genetic network 
of the cells. Here we report the generation of protein-induced neural stem cells (piNSCs) from 
human dermal fibroblasts using QQ-SON pluripotent reprogramming as a tool to quickly reset the 
time clock of the human somatic fibroblasts to a transient pluripotent state, followed by QQ-Sox2 
and QQ-NeuroD1-guided neural-lineage specific differentiation using our patented QQ-protein 
delivery technology. The generated piNSCs rely on endogenous gene expression of the NSC 
factors to express NSC markers, and resemble wild-type NSCs in their morphology, self-renewal, 
and gene expression profiles. Furthermore, the generated piNSCs indicate multipotency with the 
capability of differentiating into neurons, astrocytes, and oligodendrocytes, as confirmed by the 



































When I began studying in America, only one thing was clear; I have an opportunity that 
many from my hometown don’t. In fact, the most educated person in my village was once my 
father, whom also graduated and worked as a professor at Wayne State University (WSU). Others 
from our village deal with limited access to facilities and educational opportunities. Most families, 
like mine, sell their farming produce near the entrance of my city. Customers are those that travel 
from all over the Arabian Gulf to buy unique fruits and vegetables from the world’s largest oasis, 
AlAhsa Saudi Arabia. Today much more is clear, I know that I deserve this opportunity to 
showcase my hard work to WSU. 
In the late 1980s, my father received a full scholarship by Saudi Arabian Cultural Mission 
(SACM) to attend university in America. He quickly established his interests, and within a few 
years, I was able to attend the Crestwood School District, volunteer at the Young Muslim 
Association, and become an Eagle Scout with the Boy Scouts of America right here in Michigan. 
This was followed by SACM funding me to attend Eastern Michigan University (EMU), and 
Wayne State University (WSU). Throughout my life, I have faced many unexpected and 
challenging experiences, all of which have shaped me to become the man I ‘am today. 
My research experiences led me to discover that I truly enjoy theory work. Graduate 
research taught me about writing a thesis and dealing with the hardships that follow. It also gave 
me the chance to become more acquainted with the essentials. Furthermore, when I began my 
master’s degree, I was specifically targeting a challenging research project, one that could allow 
me to flaunt my knowledge and determination. I was seeking an advisor that was agile and 
resourceful yet aggressive in their teaching style, like my father. I knew if I could satisfy Dr. Wang, 
others wouldn’t question my hard-working ethic. Moreover, after some time working in the Wang 
lab, I realized that although my interest in science began ten years ago, my obsession initiated 
during this graduate research. 
 
 
